

**UNIVERSIDADE ESTADUAL DO OESTE DO PARANÁ - CAMPUS DE CASCAVEL**  
**CENTRO DE CIÊNCIAS BIOLÓGICAS E DA SAÚDE**  
**PROGRAMA DE PÓS-GRADUAÇÃO *STRICTO SENSU* EM BIOCÊNCIAS E**  
**SAÚDE - NÍVEL MESTRADO**

**CAROLINE COVATTI**

**AVALIAÇÃO DE UM MODELO ANIMAL DE PARALISIA CEREBRAL**  
**SOBRE A MORFOLOGIA DO MÚSCULO EXTENSOR LONGO DOS**  
**DEDOS**

CASCAVEL - PR

(Junho/2016)

**CAROLINE COVATTI**

**AVALIAÇÃO DE UM MODELO ANIMAL DE PARALISIA CEREBRAL  
SOBRE A MORFOLOGIA DO MÚSCULO EXTENSOR LONGO DOS  
DEDOS**

Dissertação apresentada ao Programa de Pós-graduação *Stricto Sensu* em Biociências e Saúde - Nível Mestrado, do Centro de Ciências Biológicas e da Saúde, da Universidade Estadual do Oeste do Paraná, como requisito parcial para obtenção do título Mestre em Biociências e Saúde.

Área de concentração: Fatores que influenciam a morfofisiologia orgânica.

ORIENTADORA: Prof<sup>a</sup>. Dr<sup>a</sup>. Márcia Miranda  
Torrejais

COORIENTADORA: Prof<sup>a</sup>. Dr<sup>a</sup>. Lígia Aline  
Centenaro

CASCADEL - PR

(Junho/2016)

## DEDICATÓRIA

Dedico este trabalho a todos os envolvidos nos dois anos de mestrado que, de alguma forma, me apoiaram, acreditaram e estiveram presentes nos momentos bons e ruins.

## AGRADECIMENTOS

Agradecer aos envolvidos no trabalho é uma missão muito gratificante, pois nos mostra a quantidade de pessoas que estiveram ao nosso lado nesse momento desafiador. Agradeço, primeiramente, aos meus pais, que estiveram comigo em todo o decorrer desta trajetória. Além de um lar, me deram apoio, esperança, incentivo, me ensinando sempre a ser forte e nunca desistir quando as coisas foram difíceis. Ao meu irmão, que é o maior presente que meus pais poderiam ter me dado. Com ele aprendo a sempre ser melhor, sua educação, gentileza, amizade e companheirismo me ajudaram muito em todos os momentos. Agradeço ao Rodrigo, por ter estado ao meu lado me escutando, me dando forças, me encorajando, torcendo pelo meu sucesso e felicidade, você é muito importante. E à minha avó, Brasilina, que esteve em orações comigo durante toda essa fase, que torceu pelo bom andamento do experimento, que se interessou pela pesquisa e que ficou tão ansiosa quanto eu pelos resultados.

No âmbito acadêmico, inúmeras pessoas contribuíram para a construção deste trabalho, mas, sem dúvida, a que merece o meu profundo agradecimento, é minha orientadora, a Prof<sup>a</sup>. Dra. Márcia Miranda Torrejais. Ela depositou em mim toda a sua confiança, sem nem mesmo me conhecer. Me deu oportunidade de aprender, errar e acertar durante todas as etapas do trabalho. Fez sempre o possível e o impossível para o andamento do projeto de pesquisa, e correu atrás de coisas que nem seriam de responsabilidade dela. Transmitiu conhecimento com muita paciência e dedicação, e me fez crescer muito profissionalmente. À minha coorientadora, Prof<sup>a</sup>. Lígia Aline Centenaro, que foi fundamental para a realização dessa pesquisa. Ela me auxiliou durante todo o experimento, ensinou o manuseio com os animais, coordenou a equipe de realização do experimento, comandou reuniões de estudos (que agregaram muitos conhecimentos e questionamentos), disponibilizou seu tempo para vir nos ajudar até mesmo em feriados e finais de semana. Deu dicas e apontamentos de grande valia para o desenvolvimento do artigo e foi muito criteriosa durante as correções de todos os tópicos deste trabalho. Agradeço aos professores: Dr. Carlos Augusto Nassar, Dr<sup>a</sup>. Célia Cristina Leme Beu, Dr<sup>a</sup>. Rose Meire Costa Brancalhão, os quais participaram das bancas do projeto e da qualificação e auxiliaram com suas experiências, quando deram sugestões que fizeram deste um trabalho melhor. Ao técnico de laboratório, José Carlos Cintra (Zé),

que esteve sempre disposto a ajudar, e sempre resolveu os problemas inesperados do laboratório; além de ser um grande profissional, tornou-se um grande amigo. Aos professores da UNESP - Campus Botucatu, Prof<sup>a</sup>. Dr<sup>a</sup>. Selma Maria Michelin Matheus, que cedeu o laboratório para a realização de parte das análises. Também forneceu reagentes para que conseguíssemos fazer mais análises, além das caronas que foram de grande ajuda. Agradeço imensamente por nos receber de braços e portas abertas. Gostaria de agradecer também ao técnico de laboratório do Departamento de Anatomia, Gelson Rodrigues, que me auxiliou a confeccionar lâminas, me ensinou e deu dicas importantes sobre laboratório, que me apresentou o campus e pessoas de Botucatu, me concedeu caronas e momentos de descontração.

Não posso deixar de agradecer aos meus colegas de laboratório, que estiveram presentes direta ou indiretamente na pesquisa. Em especial à Bruna, que transmitiu todos os seus conhecimentos sobre laboratório, que teve paciência em explicar todos os passos das técnicas e que esteve comigo me orientando nas primeiras lâminas que confeccionei. À Pâmela, que me auxiliou durante o experimento, nas etapas da pesquisa e que dividiu comigo não apenas a bancada de laboratório, mas também alegrias, aflições e incertezas.

A todos os outros colegas: Heloísa, Remateiro, Drika, Bruno, Wellington, Suellen, muito obrigada pelos momentos de descontração, pelas risadas, pelos conselhos, dicas e histórias engraçadas que fizeram com que esses dois anos fossem mais leves e divertidos. Aos meus amigos da vida: Josi, Isa, Paula, Helena, Gih, Cami, Ana, Ângelo e Uéslei, obrigada por me proporcionar momentos únicos; por me escutarem e estarem sempre nos momentos bons e ruins. Obrigada por torcerem pelo meu sucesso e aceitarem minha ausência em muitos momentos.

## RESUMO GERAL

A paralisia cerebral (PC) caracteriza-se por distúrbios do movimento e da postura, por isso causam limitação na atividade do indivíduo, as quais são atribuídas por distúrbios não progressivos que ocorreram no desenvolvimento cerebral fetal ou infantil. Modelos animais têm sido utilizados na tentativa de reproduzir as lesões e características da PC. Porém, ainda não existe uma intervenção capaz de reproduzir as características desta patologia no âmbito experimental. Assim, o objetivo deste estudo foi verificar os efeitos de um modelo de PC que associa exposição pré-natal ao lipopolissacarídeo (LPS), anóxia perinatal e restrição sensório-motora sobre as fibras musculares e junções neuromusculares (JNMs) do músculo extensor longo dos dedos (EDL) de ratos. Filhotes *Wistar* machos foram separados em dois grupos: Grupo controle (CTL - n = 10) - filhotes de mães injetadas com solução salina durante a gestação e Grupo Paralisia Cerebral (PC - n = 10) - filhotes de mães injetadas com LPS durante a gestação, submetidos à anóxia perinatal e à restrição sensório-motora. No dia do nascimento, os filhotes do grupo PC foram colocados em câmara fechada com fluxo de nitrogênio (100%) para a realização da anóxia perinatal. A partir do primeiro dia pós-natal (P1) até o P30, esses filhotes também foram submetidos à restrição sensório-motora por imobilização das patas pélvicas. Avaliações do desempenho motor foram realizadas em um campo aberto no P29 e P45 para os dois grupos. Após a eutanásia, amostras do músculo EDL foram processadas para análise morfológica e morfométrica das fibras musculares e JNMs. Quanto à performance motora, o tempo de locomoção e o número de erguidas (*rearing*) foi significativamente menor no grupo PC em comparação ao CTL aos 29 dias de idade ( $p < 0,001$  e  $p < 0,01$ , respectivamente). Aos 45 dias de idade, o tempo de locomoção dos animais do grupo PC também foi menor em relação ao grupo CTL ( $p < 0,05$ ). O peso corporal, peso e comprimento do músculo EDL foram 18%, 17% e 15% menores, respectivamente, no grupo PC em relação ao CTL. Os animais do grupo PC apresentaram hipertrofia das fibras do tipo IIB, todavia, não houve diferença entre os grupos nas demais fibras. Não teve diferenças entre os grupos estudados quanto ao número de fibras musculares dos tipos I, IIA e IIB. A relação núcleo/fibra, e a relação capilar/fibra, foi significativamente maior no grupo PC (21% e 18%, respectivamente). Quanto às fibras intrafusais, os animais do grupo PC apresentaram atrofia de 26% na área de secção transversal e redução de 26% na área do fuso muscular. O colágeno intramuscular aumentou 34% nos animais do grupo PC. O estudo ultraestrutural do músculo EDL do grupo PC mostrou desarranjo miofibrilar, desorganização e dissolução da linha Z. As JNMs do grupo PC apresentaram aumento de 22% na área e de 11% no diâmetro maior quando comparado ao grupo CTL. Em conclusão, o modelo animal de PC que utiliza injeções de LPS, anóxia perinatal e restrição sensório-motora produz déficits motores que também são observados em crianças com PC.

**Palavras-chave:** modelo animal de paralisia cerebral; lipopolissacarídeo; anóxia perinatal; restrição sensório-motora; morfologia muscular.

## GENERAL ABSTRACT

Cerebral palsy (CP) is characterized by movement and postural disorders that limit the individual's activity, and is attributed to the occurrence of non-progressive disturbances during the development of the fetal or infant brain. Animal models have been used in an attempt to reproduce the lesions and characteristics of CP. However, there is still no intervention capable of reproducing the characteristics of this pathology in the experimental area. Thus, the objective of this study was to verify the effects of a CP model that combines prenatal exposure to lipopolysaccharide (LPS), perinatal anoxia and sensorimotor restriction on the muscle fibers and neuromuscular junctions (NMJs) of the *extensor digitorum longus* (EDL) of rats. Male Wistar pups were separated into two groups: Control group (CTL - n = 10) - pups of mothers injected with saline during pregnancy and Cerebral Palsy Group (CP - n = 10) - pups of mothers injected with LPS during pregnancy. submitted to perinatal anoxia and sensorimotor restriction. On the day of birth, the offspring of the CP group were placed in a closed chamber with nitrogen flow (100%) to perform the perinatal anoxia. Additionally, from the first postnatal day (P1) to P30, those pups were also submitted to sensorimotor restriction by immobilizing the hind limbs. Motor performance was assessed in both groups during open field tests on P29 and P45. After euthanasia, EDL muscle samples were processed for morphological and morphometric analysis of the muscle fibers and NMJs. Regarding motor performance, the time of locomotion and the number of rearings were significantly lower in the CP group compared to CTL group at 29 days of age ( $p < 0.001$  and  $p < 0.01$ , respectively). At 45 days of age, the time of locomotion of the animals in the CP group was also lower in relation to the CTL group ( $p < 0.05$ ). The total body weight, weight and length of the EDL muscle were 18%, 17% and 15% lower, respectively, in the CP group in relation to the CTL. The animals in the CP group presented hypertrophy of the type IIB fibers. However, regarding the other fibers there was no difference between groups. There were no differences between groups in the number of muscle fiber types I, IIA and IIB. The nuclei/fiber ratio, and the capillary/fiber ratio, were significantly higher in the CP group (21% and 18%, respectively). Regarding the intrafusal fibers, the animals from the CP group presented atrophy in 26% of the cross-sectional area and a reduction of 26% in the muscle spindle area. Intramuscular collagen increased by 34% in the animals from the CP group. The ultrastructural study of the EDL muscle in the CP group showed myofibrillar disruption and Z-line disorganization and dissolution. The NMJs in the CP group presented an increase of 22% in area and 11% in diameter when compared to the CTL group. In conclusion, the CP animal model that uses injections of LPS, perinatal anoxia and sensorimotor restraint produces motor deficits that are also observed in children with CP.

**Keywords:** animal model of cerebral palsy; Lipopolysaccharide; Perinatal anoxia; Sensorimotor restriction; Muscular morphology.

## SUMÁRIO

<b>LISTA DE ILUSTRAÇÕES</b> .....	ix
<b>LISTA DE TABELAS</b> .....	xii
<b>LISTA DE ABREVIATURAS</b> .....	xii
<b>INTRODUÇÃO GERAL</b> .....	12
<b>REVISÃO DE LITERATURA</b> .....	15
<b>Incidência, fisiopatologia, classificação e diagnóstico da PC</b> .....	15
<b>Músculo Estriado Esquelético e Alterações na Paralisia Cerebral</b> .....	18
<i>Características do músculo estriado esquelético e das JNMs</i> .....	18
<i>Estudos em Humanos com PC</i> .....	21
<i>Modelos animais de PC</i> .....	22
<b>REFERÊNCIAS BIBLIOGRÁFICAS</b> .....	24
<b>ARTIGO CIENTÍFICO</b> .....	30
<b>ANEXO A:</b> .....	58
<b>ANEXO B:</b> .....	59



## LISTA DE ILUSTRAÇÕES

### DISSERTAÇÃO

**Figura 1** - Esquema da estrutura de uma JNM e seus principais constituintes. Adaptado de Martyn; Fagerlund; Eriksson, 2009 .....20

### ARTIGO CIENTÍFICO

**Figure 1** - Photomicrographs of EDL muscle fibers from Wistar rats at 48 days of age. Cross section, HE staining. CTL (**A** and **C**) and CP (**B** and **D**) groups. **A** and **B**: Note the perimysium (thick arrows), endomysium (long arrows). **C** and **D**: Note the peripheral nuclei (white arrows), muscle spindle capsule (thick arrows), intrafusal fibers (arrow heads) and capillaries (thin arrows).....53

**Figure 2** - Photomicrographs of the collagen quantification in the EDL muscle of Wistar rats at 48 days of age. Longitudinal section, Masson trichrome. **A** and **B**: Note the perimysium (short arrow) and endomysium (long arrow) in the animals from the CTL and CP groups, respectively. **C**: Percentage of the intramuscular collagen of the animals from the CTL and CP groups. Values expressed as mean  $\pm$  standard deviation. \*\*Represents  $p < 0.01$ ; Student's *t*-test. ....54

**Figure 3** - Photomicrographs of the NADH-TR reaction in the EDL muscle fibers of Wistar rats at 48 days of age. Cross section. **A** and **B**: Morphology of the different types of muscle fibers in the CTL and CP groups, respectively. Fibers with small diameter (I), intermediate diameter (IIA) and large diameter (IIB). **C**: Cross-sectional area of the different types of muscle fibers observed in the EDL muscle in rats from the CP and CTL groups. **D**: Number of muscle fibers of types I, IIA and IIB observed in the EDL muscle of rats from the CP and CTL groups. Values expressed as mean  $\pm$  standard deviation. Two-way ANOVA, *post-hoc* Bonferroni test. ....55

**Figure 4** - Transmission electro-micrographs of 48-day-old rat EDL muscle in longitudinal section. **A**: CTL Group - Organized myofibrils (short arrow) and alignment of the Z line (long arrow). **B**: CP Group - Myofibrils, sparse or loosely arranged (short arrow), disorganization (long arrow) and dissolution of the Z line (arrowhead). Bar = 1 $\mu$ m. **C**: Values expressed as mean  $\pm$  standard deviation. Z-line dissolution: Mann Whitney test. Other parameters: Student's *t*-test.....56

**Figure 5** - Photomicrographs of the NMJs observed in the EDL muscle of Wistar rats at 48 days of age. Longitudinal section, Non-specific esterase reaction. **A** and **B**: Morphological characteristics of the NMJs of the animals from the CTL and CP

groups. **C**, **D** and **E**: Area, largest diameter and smallest diameter of the NMJs of the animals from the CTL and CP groups, respectively. Values expressed as mean  $\pm$  standard deviation. \*\*\*Represents  $p < 0.001$ ; \*Represents  $p < 0.05$ . Smallest diameter of NMJs: Mann Whitney test. Other parameters: Student's  $t$ -test.....57

## LISTA DE TABELAS

### ARTIGO CIENTÍFICO

**Table 1.** Locomotor variables of the animals from the CTL and CP groups evaluated in the open field at 29 and 45 days of age.....50

**Table 2.** Body weight and EDL muscle weight and length in rats at 48 days of age. 51

**Table 3.** Morphometry of the EDL muscle and muscle spindles from the CTL and CP groups at 48 days of age. ....52

## LISTA DE ABREVIATURAS

ACh	Acetilcolina
CEUA	Comitê de Ética no Uso de Animais
COBEA	Colégio Brasileiro de Experimentação Animal
CTL	Controle
EDL	Extensor longo dos dedos
G	Gramas
G	Dia gestacional
HE	Hematoxilina-eosina
HI	Hipóxico-isquêmico
IL-1b	Interleucina – 1b
JNM	Junção neuromuscular
JNMs	Junções neuromusculares
LABEM	Laboratório Experimental de Morfologia
LPS	Lipopolissacarídeo
LPV	Leucomalácia periventricular
mm	Milímetros
mATPase	ATPase miofibrilar
µm	Micrômetros
N	Número amostral
N <sub>2</sub>	Nitrogênio
NADH-TR	Nicotinamida adenina dinucleotídeo - tetrazolium reductase
O <sub>2</sub>	Oxigênio
TF	Tampão fosfato
P	Dia pós-natal
PC	Paralisia cerebral
SNC	Sistema nervoso central

## INTRODUÇÃO GERAL

Conceitua-se paralisia cerebral (PC) como uma encefalopatia crônica da infância, que causa distúrbios motores em diferentes graus de severidade (ROTTA, 2002). De acordo com o Ministério da Saúde (BRASIL, 2013), a incidência de PC é de sete a cada 1000 nascidos vivos em países subdesenvolvidos, portanto é a causa mais comum de deficiência física. As desordens encefálicas frequentemente observadas nesta patologia são as lesões de substância branca, do córtex cerebral, da medula espinal e do tronco encefálico (KOMAN; SMITH; SHILT, 2004). Crianças com PC apresentam padrões de movimentos escassos, monótonos e estereotipados e não possuem complexidade, variação e fluência (HADDERS-ALGRA, 2004). As alterações musculoesqueléticas observadas nesses pacientes incluem atrofia ou hipertrofia das fibras musculares, aumento do tecido conjuntivo na musculatura, malformação óssea secundária e degeneração da cartilagem, os quais são devido aos déficits na execução de movimentos espontâneos (COQ *et al.*, 2008; GRAHAM; SELBER, 2003). Assim, apesar de ser considerada uma lesão cerebral não progressiva, as alterações motoras na PC tendem a se agravar com o passar do tempo (GRAHAM; SELBER, 2003).

Familiares de pacientes com PC relatam dificuldades em relação a transportes especiais, preconceito da sociedade e sensação de desamparo em relação ao suporte profissional (SIMÕES *et al.*, 2013). A qualidade de vida dos cuidadores primários de crianças com PC também é prejudicada, principalmente pelas visitas frequentes ao médico, uso de medicações e hospitalizações (PRUDENTE; BARBOSA; PORTO, 2010). Foram aplicados questionários aos pacientes adultos portadores da doença e, verificou-se que poucos possuíam

índices de ensino superior, enquanto apenas 24% dos pacientes com PC em graus leves da doença tinham atividades laborais em tempo integral (ANDERSSON; MATTSON, 2001).

Tendo em vista o impacto dessa condição clínica sobre a vida do indivíduo com PC e de sua família, estudos com modelos animais estão sendo desenvolvidos para reproduzir os sinais, sintomas e os achados encefálicos e musculoesqueléticos encontrados em pacientes com PC (COQ *et al.*, 2008; DELCOUR *et al.*, 2011; LUBICS *et al.*, 2005; MARCUZZO *et al.*, 2010; STRATA *et al.*, 2004).

Um estudo prévio utilizando anóxia perinatal e restrição sensório-motora para a indução da PC registrou aumento do tônus muscular, alterações na marcha e redução na taxa de crescimento dos animais (STRATA *et al.*, 2004). Em outro estudo utilizando o mesmo modelo de lesão, a restrição sensório-motora atrasou a aquisição dos marcos do desenvolvimento e produziu alterações histológicas no córtex somatossensorial primário, o que pode contribuir para o desenvolvimento de déficits sensório-motores (MARCUIZZO *et al.*, 2010). A exposição pré-natal de filhotes de ratos à endotoxina bacteriana através de injeções de lipopolissacarídeo (LPS) também pode contribuir para a reprodução das características da PC em animais experimentais. Estudos anteriores revelam que a administração de LPS durante o período gestacional pode produzir lesões na substância branca, semelhantes às observadas em pacientes com a mesma patologia (ROUSSET *et al.*, 2013).

Quanto ao sistema musculoesquelético, a indução de um modelo animal de PC que associa a exposição pré-natal de filhotes de ratos ao LPS, anóxia perinatal e restrição sensório-motora produziu atrofia muscular nos músculos tibial anterior e sóleo, além de transição do tipo de fibra lenta para rápida com repercussões negativas sobre as habilidades motoras desses animais (STIGGER *et al.*, 2011). Entretanto, a ampla caracterização dos déficits produzidos pelo modelo animal de PC, que associa essas três intervenções, ainda não foi realizada. Assim, o objetivo deste estudo foi verificar os efeitos da associação de injeções pré-natais de LPS, anóxia perinatal e restrição sensório-motora sobre as fibras musculares e JNMs do músculo extensor longo dos dedos (do inglês, EDL) em filhotes de ratos, visando à reprodução de achados patológicos observados em pacientes com PC. A investigação detalhada das possíveis alterações que este modelo animal causa sobre diferentes músculos e junções neuromusculares (JNMs) pode nortear o

desenvolvimento de novas terapias para a recuperação funcional de pacientes com PC.

## REVISÃO DE LITERATURA

### **Incidência, fisiopatologia, classificação e diagnóstico da PC**

A PC refere-se a um conjunto de distúrbios do movimento e da postura, atribuídas a lesões não progressivas que ocorreram durante o desenvolvimento cerebral (ROSENBAUM *et al.*, 2005). A incidência mundial da PC é estimada em cerca de 2 a cada 1000 nascidos vivos, porém, pode variar devido à escassez de registros formais (PANETH; HONG; KORZENIEWSKI, 2006). Em países subdesenvolvidos, tal patologia pode acometer sete em cada 1000 nascidos vivos, e ser considerada a causa mais comum de deficiência física (MANCINI *et al.*, 2002). No Brasil, sabe-se que existe ocorrência maior dessa patologia no sexo masculino, sendo o tipo espástico o mais frequente (BRASIL, 2013).

Fatores pré-natais que ocorrem desde a concepção até antes do nascimento como infecções e parasitoses (rubéola, toxoplasmose, citomegalovírus, HIV), exposição a radiações diagnósticas ou terapêuticas, intoxicações por drogas, álcool, tabaco, pesticidas e medicações, diabetes mellitus, hipertensão, anemia grave, desnutrição, idade avançada, traumatismos e alterações anatomopatológicas (nó no cordão umbilical, cordão umbilical curto, malformações do cordão umbilical) são condições descritas em cerca de 70-80% dos casos de PC (KRIGGER, 2006; DODGE, 2008; JOHNSTON; HOON JUNIOR, 2006; ROTTA, 2002; McINTYRE *et al.*, 2013).

O período perinatal estende-se desde o início do trabalho de parto até 6 horas após o nascimento (ABPC, 2014). Eventos ocorridos nessa fase, tais como



asfixias, desproporção cefálico-pélvica e prematuridade, representam risco de 6% para o desenvolvimento de PC (KRIGGER, 2006; ROTTA, 2002). As asfixias pré e perinatal causam extenso comprometimento cerebral do recém-nascido, e são consideradas as principais causas de morbidade neurológica que levam à PC (COLVER; FAIRHURST; PHAROAH, 2014; ROTTA, 2002).

Fatores de risco pós-natais acontecem durante a infância e são associados a aproximadamente 10-20% dos casos de PC (JOHNSTON; HOON JÚNIOR, 2006; KRIGGER, 2006). Nessa fase, os danos cerebrais podem ser causados por infecções, hiperbilirrubinemia, traumas, distúrbios metabólicos como hipocalcemia, hipoglicemia, hipomagnesemia e desnutrição (DODGE, 2008; JOHNSTON; HOON JUNIOR, 2006; McINTYRE *et al.*, 2013; ROTTA, 2002).

As lesões encefálicas mais comumente observadas na PC são a leucomalácia periventricular (LPV), hemorragias intraventriculares e isquemia transitória ou irreversível (com necrose celular secundária) (KOMAN; SMITH; SHILT, 2004). A LPV caracteriza-se por necrose focal e gliose difusa da substância branca. Esse tipo de lesão também provoca perturbação da maturação de células da linhagem oligodendroglial, levando à hipomielinização e à formação de cistos e cicatrizes na substância branca (FOLKERTH, 2005). Sugere-se que infecções maternas aumentam o risco do desenvolvimento fetal de LPV, uma vez que a resposta inflamatória sistêmica fetal contribui para a ocorrência de lesões da substância branca (WU; COLFORD, 2000).

Bebês nascidos prematuros, como é o caso de parte dos pacientes com PC, apresentam fragilidade dos vasos sanguíneos intracerebrais e oscilações no fluxo sanguíneo cerebral. Assim, esses bebês são mais vulneráveis ao desenvolvimento de hemorragias intraventriculares (JOHNSTON; HOON JUNIOR, 2006). Além disso, a autorregulação do fluxo sanguíneo cerebral é um mecanismo de proteção que mantém a velocidade do fluxo sanguíneo cerebral estável em crianças normais, independentemente de variações da pressão arterial sistêmica. Tal controle ocorre por modificações do tônus arteriolar cerebral, induzidas por secreção de alguns fatores humorais. Tais mecanismos são funcionalmente imaturos em crianças prematuras. Devido a esse fato, a hipertensão sistêmica pode causar fenômenos hemorrágicos, enquanto a hipotensão sistêmica pode causar fenômenos isquêmicos (DISTEFANO; PRATICÒ, 2010). Os eventos hipóxico-isquêmicos (HI) promovem apoptose e necrose neuronal. Neurônios imaturos de recém-nascidos são mais

susceptíveis à morte apoptótica do que neurônios maduros de adultos. Por este motivo, a HI predomina como a principal causa de PC (McLEAN; FERRIERO, 2004).

As manifestações clínicas apresentadas pelos pacientes com PC dependem da distribuição topográfica, gravidade e extensão da lesão encefálica (ABPC, 2014; MY CHILD™, 2014). Os principais sinais e sintomas observados nesses pacientes incluem comprometimentos do tônus muscular, das funções motoras grossas e finas, do equilíbrio dos reflexos e da postura (MY CHILD™, 2014). Déficits auditivos e visuais, convulsões, dificuldades de aprendizagem e transtornos de linguagem também são comumente observados em pacientes com PC (DODGE, 2008; KRIGGER, 2006; ROTTA, 2002).

A PC pode ser classificada em espástica, discinética e atáxica (de acordo com o comprometimento motor observado). A PC espástica é a mais comum, além de ser caracterizada por padrões anormais de postura e/ou movimento, aumento do tônus muscular e reflexos patológicos (hiperreflexia e/ou sinais de liberação piramidal). A forma discinética está presente em 16% dos casos de PC e pode ser subdividida em formas distônica (onde ocorre hipocinesia associada à hipertonia) e coreoatetoide (caracterizada por uma hipercinesia e hipotonia). A forma mais rara é a atáxica, a qual perfaz 5% dos casos de PC, e ocorre principalmente em crianças nascidas a termo. Nessa última, ocorre perda de coordenação, alteração de força, do ritmo e da metria do movimento (CANS, 2000; HIMPENS *et al.*, 2008; KRIGGER, 2006).

Mesmo após avanços tecnológicos significativos, o diagnóstico da PC continua sendo clínico (DODGE, 2008). Atrasos no desenvolvimento motor normal, tônus muscular anormal, postura incomum e persistência de reflexos primitivos são alertas iniciais para o diagnóstico de PC (KRIGGER, 2006). Outras ferramentas usadas para avaliar a extensão da lesão no SNC são exames de imagem, como a ressonância magnética, tomografia computadorizada e ultrassonografia de crânio (KOMAN; SMITH; SHILT, 2004). Preconiza-se que o tratamento não seja adiado pela espera diagnóstica ou avaliação etiológica, mas deve ser iniciado precocemente (DODGE, 2008).

## **Músculo Estriado Esquelético e Alterações na Paralisia Cerebral**

### *Características do músculo estriado esquelético e das JNMs*

As fibras musculares adultas são células alongadas e cilíndricas que possuem capacidade contrátil. Tais fibras são multinucleadas e os núcleos se localizam principalmente na periferia da célula (DAL PAI-SILVA; CARVALHO, 2007). O citoplasma das fibras musculares é denominado sarcoplasma e é constituído por miofibrilas. As proteínas contráteis dentro de uma miofibrila estão dispostas em unidades idênticas chamadas de sarcômeros. A organização dos sarcômeros em série confere a aparência estriada ao músculo (DAL PAI-SILVA; CARVALHO, 2007).

Em um músculo, as fibras estão organizadas em feixes chamados de fascículos, os quais são unidos por tecido conjuntivo. A camada de tecido conjuntivo que recobre o músculo inteiro é chamada de epimísio. No interior do músculo, com a separação dos fascículos, encontram-se finos septos de tecido conjuntivo, o perimísio. Mais internamente, encontra-se o endomísio, o qual envolve cada fibra muscular individualmente (JUNQUEIRA; CARNEIRO, 2013).

Os músculos são ainda constituídos por fusos musculares, localizados profundamente ao ventre muscular e são formados por fibras intrafusais especializadas. As fibras intrafusais são inervadas por neurônios sensoriais, monitoram as mudanças na extensão e taxa de alongamento dos fascículos musculares e transmitem a informação para o SNC, o qual responde, imediatamente, com ajustes corretivos à tonicidade dos grupos musculares (ZVARITCH; MACLENNAN, 2015).

A musculatura esquelética é constituída por tipos de fibras musculares que apresentam características morfológicas e funcionais distintas (MINAMOTO, 2005). Brooke e Kaiser (1970), com base na ATPase miofibrilar (mATPase) em meio de incubação em pH 9,4, precedido de pré-incubação em meios ácido (pH 4,3 - 4,6) e alcalino (pH 10,4 - 10,6), classificaram as fibras em tipos I, IIA e IIB. As fibras do tipo I reagem fortemente com a pré-incubação ácida, de contração lenta; as fibras do tipo IIB reagem fortemente com pré-incubação alcalina, de contração rápida. As fibras tipo IIA respondem, de forma variada, à reação pela mATPase. Geralmente, a

reação é moderada após pré-incubação em pH alcalino e fraca após pré-incubação em pH ácido.


O músculo EDL, alvo deste estudo, contém principalmente fibras do tipo II, as quais possuem pouca quantidade de mitocôndrias, linha Z delgada e retículo sarcoplasmático altamente desenvolvido (SCHIAFFINO; HANZLÍKOVÁ; PIEROBON, 1970). O EDL origina-se no epicôndilo lateral do fêmur e divide-se em quatro tendões, inserindo-se no terceiro, quarto e quinto dedo do membro pélvico de ratos, cuja função é a extensão dos dedos (HEBEL; STROMBERG, 1976). Quando o rato está apoiado somente pelos membros pélvicos, o músculo EDL não é ativado e seu sinal na eletromiografia é quase plano. Quando o rato está andando, a atividade eletromiográfica caracteriza-se por rajadas rítmicas, que correspondem à fase de balanço do ciclo da marcha (SLAWIRISKA *et al.*, 1996).

Os músculos estriados esqueléticos de ratos são imaturos ao nascimento e mudanças importantes no tipo de fibra podem ocorrer durante as fases iniciais de desenvolvimento pós-natal (SCHIAFFINO; REGGIANI, 2011). A contração muscular espontânea produz a ativação dos fusos musculares de forma somatotópica. A interação entre sinais de retroalimentação sensorial disparados pelos movimentos e oscilações do fuso moldam a formação de conexões corticais necessárias para a coordenação sensório-motora (KHAZIPOV *et al.*, 2004). Além disso, a contração muscular é um fator importante para o desenvolvimento muscular normal e maturação das JNMs, promove o crescimento miofibrilar correto para a estabilização do receptor de acetilcolina nas JNMs (SCHIAFFINO; REGGIANI, 2011).

As JNMs são sinapses especializadas encontradas entre os motoneurônios e as fibras musculares esqueléticas (WU; XIONG; MEI, 2010). Mais especificamente, os neurônios motores inferiores que fazem parte dessas junções possuem seus corpos celulares no corno anterior da medula espinal e projetam-se até a periferia através de axônios mielinizados. Esses terminais axonais possuem acetilcolina (ACh) e ramificam-se amplamente ao se aproximarem do músculo-alvo. Devido a essa ramificação, o axônio entra contato com várias fibras musculares para formar grupos funcionais conhecidos como unidades motoras. Logo antes de atingir a fibra muscular, o axônio perde a bainha de mielina e passa a ser coberto apenas pelas células de Schwann (MARTYN; FAGERLUND; ERIKSSON, 2009).

Existe uma fenda chamada de goteira sináptica primária entre o axônio e a fibra muscular, a qual é revestida por lâmina basal e contém a enzima

acetilcolinesterase. A parte do músculo oposta ao neurônio é chamada de membrana pós-sináptica, contendo receptores para ACh e o sarcoplasma juncional, o qual suporta estrutural e metabolicamente essa região (Figura 1). Com o amadurecimento da JNM, a membrana pós-sináptica se invagina e forma as dobras juncionais. Os receptores para ACh estão concentrados apenas nas cristas destas dobras juncionais (WU; XIONG; MEI, 2010).



**Figura 1** - Esquema da estrutura de uma JNM e seus principais constituintes. Adaptado de Martyn; Fagerlund; Eriksson, 2009

De acordo com os diferentes tipos de fibras musculares, podem existir variações na forma e tamanho do terminal axônico e também na complexidade da membrana pós-sináptica. As fibras musculares do tipo I possuem JNMs com dimensões pequenas, forma arredondada ou ligeiramente elíptica, ramificação axonal grosseira com terminais axônicos dilatados, goteira sináptica rasa e dobras juncionais pouco profundas e simples. Em contrapartida, as fibras musculares do tipo IIb apresentam junções com dimensões maiores, forma elíptica, terminais axônicos finos, longos, ramificados e delicados, goteira sináptica profunda e dobras

juncionais profundas e complexas. As fibras do tipo IIA exibem junções com aspectos estruturais que ficam entre aqueles apresentados pelas fibras dos tipos I e IIB (OGATA, 1988).

As JNMs são funcionais ao nascimento, mas sofrem modificações no período pós-natal. Os terminais pré e pós-sinápticos tornam-se mais interdependentes e ocorre melhor comunicação entre os terminais nervosos e os receptores de ACh. Quando atingem a maturação, essas estruturas mantêm-se de forma estável, mas são suscetíveis à remodelação. As JNMs possuem ainda capacidade de regeneração após lesão do nervo periférico ou músculo (SANES; LICHTMAN, 1999). Em estudo realizado por Robinson *et al.* (2013), a organização das JNMs foi avaliada em crianças com PC do tipo espástica e que apresentavam escoliose. Redução das mitocôndrias nas terminações nervosas pré-sinápticas e diferenças na conformação das dobras juncionais foram observadas no músculo espinal desses pacientes. Todavia, descrições detalhadas sobre as JNMs em humanos e em modelos animais ainda são escassas.

#### *Estudos em Humanos com PC*

Para que o crescimento muscular ocorra adequadamente são necessários alongamentos musculares regulares (GRAHAM; SELBER, 2003). Na maioria dos casos de PC, os músculos não relaxam devido à presença da espasticidade (MARBINI *et al.*, 2002). Assim, pode ocorrer uma redução do volume do ventre associado ao encurtamento muscular nesses pacientes (MALAIYA *et al.*, 2007). Tais alterações musculares podem causar uma torção dos ossos longos, instabilidade articular e alterações degenerativas prematuras em articulações (GRAHAM; SELBER, 2003). Consequentemente, crianças com PC apresentam redução da atividade motora devido à fraqueza, à dor e à falta de equilíbrio (GRAHAM; SELBER, 2003).

As crianças com PC do tipo espástico podem apresentar aumento na quantidade de colágeno muscular, o que pode contribuir para o aparecimento de rigidez (BOOTH; CORTINA-BORJA; THEOLOGIS, 2001). Análises ultraestruturais de biópsias realizadas no músculo adutor longo e tríceps sural de crianças com PC também mostram desorganização ou desorientação de miofibrilas, alterações mitocondriais (degeneração, agregação, polimorfismo e hiperplasia) e alteração

nuclear (núcleos picnóticos) (MARBINI *et al.*, 2002). Músculos espásticos apresentam ainda redução no comprimento do sarcômero em repouso (FORAN *et al.*, 2005). E, apesar de não ter qualquer anormalidade muscular específica desta patologia, mudanças na distribuição do tipo de fibra (predominância de fibras do tipo I) e variações no tamanho da fibra muscular (hipertrofia das fibras do tipo II) são alterações vistas em biópsias do músculo gastrocnêmio de pacientes jovens (ITO *et al.*, 1996).

### *Modelos animais de PC*

A PC é resultado da interação de múltiplos fatores de risco, que podem agir em diferentes momentos do desenvolvimento do SNC (ROSENBAUM *et al.*, 2005). Por tais motivos, as alterações anatomopatológicas observadas nessa encefalopatia crônica são variáveis (ROTTA, 2002). Assim como em humanos, ao considerarmos modelos animais de PC, o momento e a natureza da lesão podem produzir diferentes fenótipos (CLOWRY, 2014).

Em filhotes de ratos, a infecção induzida através de injeções de LPS no período pré-natal pode causar lesões na substância branca, possivelmente devido à produção de citocinas inflamatórias (DAMMANN; DURUM; LEVITON, 2001; WANG *et al.*, 2006). A anóxia perinatal leva ao aumento do tônus muscular, alterações na marcha e desorganização no córtex motor primário (STRATA *et al.*, 2004). Além disso, a restrição sensório-motora no período pós-natal produz redução do peso corporal e da densidade óssea e prejuízos no desempenho motor em testes de caminhada e em escadas (MARCUIZZO *et al.*, 2010).

Filhotes de ratos expostos à infecção por LPS associada com anóxia perinatal apresentam déficits na coordenação motora e diminuição dos movimentos espontâneos mais graves do que filhotes expostos à LPS ou anóxia perinatal isoladamente (GIRARD *et al.*, 2009). Quando foi realizada a combinação de anóxia perinatal e a restrição sensório-motora, houve aumento do colágeno e alterações na matriz do tecido conjuntivo nos músculos glúteo máximo, quadríceps femoral e tríceps sural (COQ *et al.*, 2008). Esse segundo tipo de associação causou também atrofia no músculo sóleo e diminuição do comprimento da passada (MARCUIZZO *et al.*, 2008).

Stigger *et al.* (2011) realizaram estudo com injeções de LPS, anóxia perinatal e restrição sensório-motora em associação ou isoladamente. Nos testes motores, todos os grupos submetidos à restrição sensório-motora apresentaram resultados significativamente inferiores devido à falta de fluência e coordenação. Porém, a associação dos três insultos produziu os piores desempenhos nos testes motores realizados. Além disso, a atrofia muscular do tibial anterior somente foi observada no grupo onde houve tal associação. Acredita-se que a restrição sensório-motora imita a imobilidade induzida pela espasticidade, enquanto a associação com LPS e anóxia perinatal desempenham importante papel na reprodução de um fenótipo mais complexo de PC. Sendo assim, o presente estudo utilizou a associação de injeções de LPS, anóxia perinatal e restrição sensório-motora para identificar e caracterizar as alterações musculares causadas neste modelo animal de PC.



## REFERÊNCIAS BIBLIOGRÁFICAS

ABPC - ASSOCIAÇÃO BRASILEIRA DE PARALISIA CEREBRAL: Saiba Mais – Paralisia Cerebral: Perguntas e Respostas. Disponível em: <<http://www.paralisiacerebral.org.br/saibamais05.php>>. Acesso em: 31 de maio de 2014.

ANDERSSON, C.; MATTSON, E. Adults with cerebral palsy: a survey describing problems, needs, and resources, with special emphasis on locomotion. **Dev. Med. Child Neurol.**, v.43, p.76–82, 2001.

BOOTH, C.M.; CORTINA-BORJA, M.J.F.; THEOLOGIS, T.N. Collagen accumulation in muscles of children with cerebral palsy and correlation with severity of spasticity. **Dev. Med. Child Neurol.**, v.43, p.314–320, 2001.

BRASIL. Ministério da Saúde. **Diretrizes de atenção à pessoa com paralisia cerebral**. Secretaria de Atenção à Saúde - Departamento de Ações Programáticas Estratégicas, Brasília - 2013. Disponível em: <[http://bvsms.saude.gov.br/bvs/publicacoes/diretrizes\\_atencao\\_paralisia\\_cerebral.pdf](http://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_atencao_paralisia_cerebral.pdf)>. Acesso em: 14 de maio de 2014.

BROOKE, M.H.; KAISER, K.K. Three “myosin adenosine triphosphatase” systems: the nature of their pH labiality and sulfhydryl dependence. **J. Histochem. Cytochem.**, v.18, n.9, p.670-672, 1970.

CANS, C. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. **Dev. Med. Child Neurol.**, v.42, p.816-824, 2000.

CLOWRY, G.J.; BASUODAN, R.; CHAN, F. What are the best animal models for testing early intervention in cerebral palsy? **Front. Neurol.**, v.5, n.258, p.1-17, 2014.

COLVER, A.; FAIRHURST, C.; PHAROAH, P.O.D. Cerebral palsy. **Lancet.**, v.383, n. 5, p.1240-1249, 2014.

COQ, J.O.; STRATA, F.; RUSSIER, M.; SAFADI, F. F.; MERZENICH, M. M.; BYL, N. N.; BARBE, M. F. Impact of neonatal asphyxia and hind limb immobilization on musculoskeletal tissues and S1 map organization: Implications for cerebral palsy. **Exp. Neurol.**, v.210, p.95-108, 2008.

DAL PAI-SILVA, M.; CAVALHO, R.F. Mecanismos celulares e moleculares que controlam o desenvolvimento e o crescimento muscular. **R. Bras. Zootec.**, v.36 (suplemento especial), p.21-31, 2007.

DAMMANN, O.; DURUM, S.; LEVITON, A. Do white cells matter in white matter damage? **Trends NeuroSci.**, v.24, n.6, p.320-324, 2001.

DELCOUR, M.; RUSSIER, M.; XIN, D.L.; MASSICOTTE, V.S.; BARBE, M.F.; COQ, J.O. Mild musculoskeletal and locomotor alterations in adult rats with white matter injury following prenatal ischemia. **Int. J. Devl. Neuroscience** , v.29. p.593-607, 2011.

DISTEFANO, G.; PRATICÒ, A.D. Actualities on molecular pathogenesis and repairing processes of cerebral damage in perinatal hypoxic-ischemic encephalopathy. **Ital. J. Pediatr.**, v.36, n. 63, p.1-10, 2010.

DODGE, N. N. Cerebral Palsy: Medical Aspects. **Pediatr. Clin. N. Am.**, v.55, p.1189-1207, 2008.

FOLKERTH, R.D. Neuropathologic Substrate of Cerebral Palsy. **J. Child Neurol.**, v. 20, n. 12, p.940-949, 2005.

FORAN, J.R.H.; STEINMAN, S.; BARASH, I.; CHAMBERS, H.G.; LIEBER, R.L. Structural and mechanical alterations in spastic skeletal muscle. **Dev. Med. Child. Neurol.**, v. 43, p. 314-320, 2005.

GIRARD, S.; KADHIM, H.; BEAUDET, N.; SARRET, P.; SÉBIRE, G. Developmental motor deficits induced by combined fetal exposure to lipopolysaccharide and early neonatal hypoxia/ischemia: a novel animal model for cerebral palsy in very premature infants. **Neuroscience**, v.158, p.673-682, 2009.

GRAHAM, H.K.; SELBER, P. Musculoskeletal aspects of cerebral palsy. **J. Bone Joint Surg.**, v.85-B, n. 2, p.157-166, 2003.

HADDERS-ALGRA, M. General movements: a window for early identification of children at high risk for developmental disorders. **J. Pediatr.**, v.145, p.S12–S18, 2004.

HEBEL, R.; STROMBERG, M.W. **Anatomy of the laboratory rat**. Baltimore: Williams & Wilkins, 1976, p.37.

HIMPENS, E.; BROECK, C.V.; OOSTRA, A.; CALDERS, P.; VANHAESEBROUCK, P. Prevalence, type, distribution, and severity of cerebral palsy in relation to gestational age: a meta-analytic review. **Dev. Med. Child Neurol.**, v.50, p.334-340, 2008.

ITO, J.; ARAKI, A.; TANAKA, H.; TASAKI, T.; CHO, K.; YAMAZAKI, R. Muscle histopathology in spastic cerebral palsy. **Brain Dev.**, v. 18, p. 299-303, 1996.

JOHNSTON, M.V.; HOON JUNIOR, A.H. Cerebral Palsy. **Neuromol. Med.**, v.8, p.435-450, 2006.

JUNQUEIRA, L.C.; CARNEIRO, J. **Histologia Básica**. 12. ed. Rio de Janeiro: Guanabara Koogan, 2013, p.178.

KHAZIPOV, R.; SIROTA, A.; LEINEKUGEL, X.; HOLMES, G.L.; BEN-ARI, Y.; BUZSÁKI, G. Early motor activity drives spindle bursts in the developing somatosensory cortex. **Nature**, v.432, n. 9, p.758-761, 2004.

KOMAN, L.A.; SMITH, c B.P.; SHILT, J.S. Cerebral palsy. **Lancet.**, v.363, n.15, p.1619-1631, 2004.

KRIGGER, K.W. Cerebral Palsy: An Overview. **Am. Fam. Physician.**, v. 73, n.1, p.91-100, 2006.

LUBICS, A.; REELODI, D.; TAMÁS, A.; KISS, P.; SZALAI, M.; SZALONTAY, L.; LENGVARI, I. Neurological reflexes and early motor behavior in rats subjected to neonatal hypoxic–ischemic injury. **Beh. Brain Res.**, v.157, p.157-165, 2005.

MALAIYA, R.; McNEE, A. E.; FRY, N. R.; EVE, L. C.; GOUGH, M.; SHORTLAND, A.P. The morphology of the medial gastrocnemius in typically developing children and children with spastic hemiplegic cerebral palsy. **J. Electromyogr. Kinesiol.**, v. 17, p.657-663, 2007.

MANCINI, M.C.; FIÚZA, P. M.; REBELO, J. M.; MAGALHÃES, L. C.; COELHO, Z. A.C.; PAIXÃO, M. L.; GONTIJO, A. P. B.; FONSECA, S. T. Comparação do desempenho de atividades funcionais em crianças com desenvolvimento normal e crianças com paralisia cerebral. **Arq. Neuropsiquiatr.**, v.60, n.2-B, p.446-452, 2002.

MARBINI, A.; FERRARI, A.; CIONI, G.; BELLANOVA, M.F; FUSCO, C.; GEMIGNANI, F. Immunohistochemical study of muscle biopsy in children with cerebral palsy. **Brain Dev.**, v.24, p.63-66, 2002.

MARCUZZO, S.; DUTRA, M.F.; STIGGER, F.; NASCIMENTO, P.S.; ILHA, J.; KALIL-GASPAR, P.I; ACHAVAL, M. Beneficial effects of treadmill training in a cerebral palsy-like rodent model: Walking pattern and soleus quantitative histology. **Brain Res.**, v.1222, p.129-140, 2008.

MARCUZZO, S.; DUTRA, M.F.; STIGGER, F.; NASCIMENTO, P. S.; ILHA, J.; KALIL-GASPAR, P. I; ACHAVAL, M. Different effects of anoxia and hind-limb immobilization on sensorimotor development and cell numbers in the somatosensory cortex in rats. **Brain Dev.**, v.32, p.323-331, 2010.

MARTYN, J.A.J.; FAGERLUND, M.J.; ERIKSSON, L.I. Basic principles of neuromuscular transmission. **Anaesthesia**, v.64, Suppl1, p.1-9, 2009.

McINTYRE, S.; TAITZ, D.; KEOGH, J.; GOLDSMITH, J.; BADAWI, N. A systematic review of risk factors for cerebral palsy in children born at term in developed countries. **Dev. Med. Child Neurol.**, v.55, p.499-508, 2013.

McLEAN, C.; FERRIERO, D. Mechanisms of hypoxic–ischemic injury in the term infant. **Semin. Perinatol.**, v.28, p.425-432, 2004.

MINAMOTO, B. Classificação e adaptações das fibras musculares: uma revisão. **Fisioter. pesqui.**, v.12, n.3, p.50-55, 2005.

MY CHILD™ CEREBRAL PALSY FOUNDATION: About Cerebral Palsy. Disponível em: <<http://cerebralpalsy.org/about-cerebral-palsy/prevalence-of-cerebral-palsy/>>. Acesso em: 31 de maio de 2014.

OGATA, T. Structure of motor endplates in the different fiber types of vertebrate skeletal muscles. **Arch. Histol. Cytol.**, v.51, n.5, p.385-424, 1988.

PANETH, N.; HONG, T.; KORZENIEWSKI, S. The Descriptive epidemiology of Cerebral Palsy. **Clin. Perinatol.**, v.33, p.251-267, 2006.

PRUDENTE, C.O; BARBOSA, M.A; PORTO, C.C. Qualidade de vida de cuidadores primários de crianças com paralisia cerebral: revisão da literatura. **Rev. Eletr. Enf.** [Internet]., v.12, n.2, p.367-72, 2010.

ROBINSON, K.G; MENDONÇA, J.L; MILITAR, J.L.; THEROUX, M.C.; DABNEY, K.W.; SHAH, S.A.; MILLER, F.; AKINS, R.E. Disruption of Basal Lamina Components in Neuromotor Synapses of Children with Spastic Quadriplegic Cerebral Palsy. **Plos One**, v.8, n.8, p.2-16, 2013. Disponível em: < [www.plosone.org](http://www.plosone.org)>. Acesso em: 10 de outubro de 2014.

ROSENBAUM, P; BAX, M.; GOLDSTEIN, M.; PANETH, N.; JACOBSSON, B.; LEVITON, A.; DAN, B. Proposed definition and classification of cerebral palsy. **Dev. Med. Child Neurol.**, v.47, p.571-576, 2005.

ROTTA, N.T. Paralisia cerebral, novas perspectivas terapêuticas. **J. Pediatr.**, v.78, Supl.1, p.S48-S54, 2002.

ROUSSET, C. I.; KASSEM, J.; AUBERT, A.; PLANCHENAULT, D.; GRESSENS, P.; CHALON, S.; BELZUNG, C.; SALIBA, E. Maternal Exposure to Lipopolysaccharide Leads to Transient Motor Dysfunction in Neonatal Rats. **Dev. Neurosci.**, v.27, p.1-10, 2013.

SANES, J.R.; LICHTMAN, J.W. Development of the vertebrate neuromuscular junction. **Annu. Rev. Neurosci.**, v.22, n.1, p.389-442, 1999.

SCHIAFFINO, S.; HANZLÍKOVÁ, V.; PIEROBON, S. Relations between structure and function in rat skeletal muscle fibers. **J. Cell Biol.**, v.47, p.107-119, 1970.

SCHIAFFINO, S.; REGGIANI, C. Fibers types in mammalian skeletal muscles. **Physiol. Rev.**, v.91, p.1447-1531, 2011.

SIMÕES, C.C.; SILVA, L.; SANTOS, M.R; MISKO, M.D.; BOUSSO, R. S. A experiência dos pais no cuidado dos filhos com paralisia cerebral. **Rev. Eletr. Enf. [Internet]**, v.15, n.1, p.138-145, 2013. Disponível em: <<http://www.fen.ufg.br/revista/v15/n1/pdf/v15n1a16.pdf>>. Acesso em: 05 de abril de 2014.

SLAWIRISKA, U.; TYC, F.; KASICKI, S.; VRBOVÁ, G. Functional reorganization of the partially denervated hindlimb extensor and flexor muscle in rat. **Acta Neurobiol. Exp.**, v.56, p.441-447, 1996.

STIGGER, F., FELIZZOLA, A.L., KRONBAUER, G.A., COUTO, G.K., ACHAVAL, M., MARCUZZO, S. Effects of fetal exposure to lipopolysaccharide, perinatal anoxia and

sensorimotor restriction on motor skills and musculoskeletal tissue: implications for an animal model of cerebral palsy. **Exp. Neurol.**, v.228, n.2, p.183-91, 2011.

STRATA, F.; COQ, J-O.; BYL, N.; MERZENICH, M. M. Effects of sensorimotor restriction and anoxia on gait and motor cortex organization: implications for a rodent model of cerebral palsy. **Neuroscience.**, v.129, p.141-156, 2004.

WANG, X.; ROUSSET, C.I.; HAGBERG, H.; MALLARD, C. Lipopolysaccharide-induced inflammation and perinatal brain injury. **Semin. Fetal Neonatal Med.**, v.11, n.5, p.343-353, 2006.

WU, Y. W.; COLFORD, J. M. Chorioamnionitis as a risk factor for cerebral palsy. **JAMA**, v.284, n.11, p.1417-1424, 2000.

WU, H.; XIONG, W.C.; MEI, L. To build a synapse: signaling pathways in neuromuscular junction assembly. **Development.**, v.137, p.1017-1033, 2010.

ZVARITCH, E.; MACLENNAN, D.H. Muscle spindles exhibit core lesions and extensive degeneration of intrafusal fibers in the Ryr1(I4895T/wt) mouse model of core myopathy. **Biochem. Biophys. Res. Commun.**, v.460, n.1, p.34-39, 2015.

**ARTIGO CIENTÍFICO**

**AN EVALUATION OF AN ANIMAL MODEL OF CEREBRAL PALSY:  
THE EFFECTS ON THE MORPHOLOGY OF THE *EXTENSOR*  
*DIGITORUM LONGUS* MUSCLE**

**AN EVALUATION OF AN ANIMAL MODEL OF CEREBRAL PALSY:  
THE EFFECTS ON THE MORPHOLOGY OF THE *EXTENSOR  
DIGITORUM LONGUS* MUSCLE**

Caroline COVATTI, Ms<sup>a</sup>, Bruna H. ULSENHEIMER, Ms<sup>a</sup>; Pâmela BURATTI, Ms<sup>a</sup>;  
Lígia A. CENTENARO, Dra<sup>b</sup>; Ana T. B. GUIMARÃES Dra<sup>c</sup>; Rose M. C.  
BRANCALHÃO, Dra<sup>c</sup>, Marcia M. TORREJAIS, Dra<sup>c</sup>.

(a) Student on the Graduate Program - Master in Biosciences and Health, State University of Western Paraná, Cascavel, Brazil.

(b) Lecturer at the Experimental Laboratory of Morphology (LABEM), State University of Western Paraná, Cascavel, Brazil

(c) Lecturer on the Graduate Program - Master in Biosciences and Health, State University of Western Paraná, Cascavel, Brazil

Caroline Covatti

Rua Rio de Janeiro, 1547, apto 602 - Centro, Cascavel - PR, Brasil - Residencial

Rua Universitária, 1619 - Jardim Universitário, Cascavel - PR, Brasil - Institucional

Cell phone: (+55) 45 - 99944-4545

Home Phone: (+55) 45 - 3038-1779

Institutional Phone: (+55) 45 - 3220 - 3194

email: carolcovatti@hotmail.com



## ABSTRACT

**Background:** Cerebral palsy (CP) refers to a chronic childhood encephalopathy that causes movement disorders, which is the main cause of physical disability.

**Objective:** Animal models have been used in attempting to reproduce the clinical characteristics of the CP. However, as yet, there is no model capable of faithfully reproducing the findings of this clinical condition in the experimental setting. Thus, the objective of this study was to verify the effects of a CP model that combines prenatal exposure to lipopolysaccharide (LPS), perinatal anoxia and sensorimotor restriction on muscle fibers and neuromuscular junctions (NMJs) of the *extensor digitorum longus* muscle (EDL) in rats.

**Study design:** Male Wistar rat pups were separated into two groups: a) Control (CTL - n = 10) - pups of mothers injected with saline during pregnancy and b) Cerebral Palsy (CP - n = 10) - pups of mothers injected with LPS during pregnancy, and submitted to perinatal anoxia and sensorimotor restriction. Motor performance was assessed in an open field on postnatal day 29 (P29) and P45 in both groups. After euthanasia, EDL muscle samples were processed for morphological and morphometric analysis of muscle fibers and NMJs.

**Results:** Motor performance, locomotion time and number of rearings were significantly lower in the CP compared to the CTL group at 29 days of age ( $p < 0.001$  and  $p < 0.01$ , respectively). At 45 days, the locomotion time of the animals from the CP group was also shorter in relation to the CTL group ( $p < 0.05$ ). The body weight, weight and length of the EDL muscles were 16%, 16% and 15% lower, respectively, in the CP group in relation to the CTL. The animals in the CP group presented hypertrophy in the type IIB fibers, but there were no differences between the studied groups regarding the type I, IIA and IIB muscle fiber counts. The nuclei/fiber and capillary/fiber ratios were significantly higher in the CP group than in the CTL group. Regarding the intrafusal fibers, the animals from the CP group presented 26% atrophy in the cross-sectional area of these structures and 26% reduction in the muscle spindle area. Intramuscular collagen volume was 34% higher in the animals from the CP group. In the animals from the CP group, the EDL muscle showed myofibrillar disruption and Z-line disorganization and dissolution. The NMJs from the CP group presented increases of 22% in area and 11% in diameter when compared to the CTL group.

**Conclusion:** The animal model of CP using injections of LPS, perinatal anoxia and sensorimotor restraint, produces motor deficits and macro and microscopic alterations and in the ultrastructure of the EDL muscle that are also observed in patients with CP.

**Keywords:** Cerebral Palsy animal model; Lipopolysaccharide; Perinatal anoxia; Sensorimotor Restriction; *Extensor Digitorum Longus* Muscle.

## INTRODUCTION

Cerebral palsy (CP) is defined as a chronic encephalopathy that causes sensorimotor disorders at different degrees of severity<sup>1</sup>, and is considered the most common cause of physical deficiency in childhood<sup>2</sup>. CP is believed to result from the interaction of multiple pre, peri, or postnatal risk factors<sup>3</sup>. The musculoskeletal changes observed in these patients are mainly due to deficits in the execution of spontaneous movements and include atrophy or hypertrophy of the muscular fibers, increased volumes of connective tissue in the musculature, bone malformation and degeneration of the articular cartilage<sup>4,5</sup>.

An earlier study also shows that children with spastic CP may also present alterations in the organization of the neuromuscular junctions (NMJs), with reduced mitochondria in the presynaptic nerve endings and differences in the conformation of the junctional folds of the spinal muscle<sup>6</sup>. NMJs are elements of the nervous system that play a key role in transmitting signals between motor neurons and muscle fibers<sup>7</sup>. Spontaneous muscle contraction is known to be an important factor for the maturation of NMJs and normal muscle development<sup>8</sup>.

During muscle contraction, the muscle spindles are activated. These structures are located deep within the muscular belly and are formed of specialized intrafusal fibers<sup>9</sup>. Each muscle spindle is comprised of 2-10 intrafusal fibers, which are surrounded by a capsule of connective tissue. Intrafusal fibers can be classified into three types: dynamic nuclear bag fibers; static nuclear bag fibers and nuclear chain fibers<sup>10</sup>. The intrafusal fibers monitor changes in the length of the muscular fascicles and send information to the central nervous system, which responds by adjusting the tone of the muscular groups<sup>9</sup>. The sensory feedback signals triggered by the movements and oscillations of the muscle spindle lead to the formation of the cortical connections necessary for sensory-motor coordination<sup>11</sup>.

Animal models are being developed with the purpose of reproducing the signs, symptoms and brain and musculoskeletal characteristics found in CP patients<sup>4,12-15</sup>. Inducing an animal CP model that combines prenatal exposure of rats to lipopolysaccharide (LPS), perinatal anoxia and post-natal sensorimotor restriction produced muscular atrophy in the anterior *tibialis* and *soleus* muscles, the transition from type I to type II fibers and changes in the motor skills of the animals<sup>16</sup>. In this experimental model, sensorimotor restriction is believed to mimic spasticity-induced

immobility, while LPS and perinatal anoxia may mimic neuropathological findings in CP. However, a broad characterization of the muscular deficits produced by this animal model of CP in muscles in which type II fibers predominate, such as the EDL, has not yet been conducted. Therefore, the objective of this study was to investigate the effects of the combination of prenatal injections of LPS, perinatal anoxia and post-natal sensorimotor restriction on muscle fibers and NMJs in the EDL muscle in rat pups.

## **METHODOLOGY**

### **Place, animals and induction of the animal model of CP**

This research was approved by the Ethics in the Use of Animals Committee (CEUA) of UNIOESTE. During all stages of the experiment, the ethical principles recommended by the Brazilian College of Animal Experimentation (COBEA) were followed.

At the beginning of the experimental protocol, adult Wistar rats (42 females and 10 males), approximately three months old, from the UNIOESTE Central Bioterium (Animal Facility) were used. These animals were housed in polycarbonate boxes (27 x 26 x 31cm) covered wood shavings, in an environment with a 12h light/dark cycle, controlled temperature ( $20 \pm 2^{\circ}\text{C}$ ), with water and food *ad libitum*.

In order to verify the estrous cycle, the rats were submitted to daily colpocytological examination, based on the analysis of vaginal smear samples. When receptive (the proestrus phase), the females were placed with a male for mating. Pregnancy was confirmed the following morning, through the presence of spermatozoa in a second colpocytological examination. Then, some of the females were injected intraperitoneally with vehicle (n=15; 100  $\mu\text{l}$  of sterile saline); and the others with LPS (n=27; approximately 200  $\mu\text{g}/\text{kg}$  LPS in 100  $\mu\text{l}$  of sterile saline). Both injections were performed every 12 hours (07:30 and 19:30 h), as from the 17th gestational day (G17) until the end of gestation (G21).

The day of birth of the offspring was considered the postnatal day 0 (P0), when the pups were separated into two groups: 1) the Control group - pups of rats injected with saline during pregnancy (CTL, n = 10) and 2) the CP group - pups of rats injected with LPS during pregnancy, submitted to perinatal anoxia and

sensorimotor restriction (CP, n=10). Only male offspring were used in this study, as females were excluded due to the influence of sex hormones on brain development. In the first days after birth, the litters were standardized into 8 offspring (with preferential removal of females).

The offspring from the CP group underwent perinatal anoxia on P0. For this intervention, the pups were placed in a closed chamber, partially immersed in water at 37° C, with a flow of 9 L/min of nitrogen (100%) for 20 minutes. Following this procedure, the animals were quickly removed, kept under normal atmospheric conditions and observed until their normal respiratory pattern returned<sup>16</sup>. The male offspring from the CTL group were also placed in the same chamber for 20 minutes, which remained open and with normal atmospheric airflow. To avoid rejection by the mother following this intervention, direct contact by the experimenter was prevented by ensuring the pups were wrapped in wood shavings from the animal box during handling. Whenever possible, the mothers remained close to the pups, but in their housing boxes.

Finally, the pups from the CP group underwent sensorimotor restriction 16 hours/day, from the first postnatal day (P1) to P30. Restriction was achieved with the aid of adhesive microporous tape and an epoxy mold (adjusted according to the size of the animal), which allowed the hind limbs to be immobilized in an extended position. The animals from the CTL group received manipulation in the hind limbs similar to that performed on the restricted animals to prevent possible differences in brood development.

### **Evaluating the displacement time in the open field**

The locomotor activity and exploratory behavior of the animals were evaluated on P29 and P45. The test apparatus, called the open field, consisted of an arena (40 x 100 x 100 cm) with the floor subdivided into 12 squares. For each test, the animals were initially positioned in the northeast corner of the arena and removed after a period of five minutes. Each evaluation was filmed from above for later evaluation of the following parameters: number of line quadrants crossed, number of rearings, grooming frequency, total time immobile and total time mobile.

### **Sample collection**

At 48 days of age, the animals from both groups were weighed and anesthetized with an overdose of ketamine hydrochloride (50 mg/kg, ip; *Cristália*, Brazil) and xylazine hydrochloride (10 mg/kg, ip; *Cristália*, Brazil). The skin of the hind limb was folded back and the anterior tibial muscle was removed for bilateral dissection of the EDL muscle. The EDL muscle from the right antimere was then weighed and its length (muscular belly) measured using a digital caliper (Digimess®, São Paulo, Brazil). The muscles were sectioned using a stainless steel blade and prepared for histological, histoenzymological and histochemical examination.

### **The histological and histoenzymological study of the muscle fibers and quantification of intramuscular collagen**

After dissection, the proximal portions of the right antimere EDL muscle were maintained at room temperature for 30 to 40 minutes. After which, the samples were covered with neutral talc (JOHNSON'S<sup>®</sup>, São Paulo, Brazil) and frozen in liquid nitrogen for storage in a Biofreezer at -80°C. Subsequently, cross sections (7µm thick) of these samples were obtained using a cryostat (LUPETEC CM 2850 Cryostat Microtome).

Some of the sections obtained were stained using the Hematoxylin-Eosin (HE) technique<sup>17</sup>, and the slides were mounted with Permount (Fisher Scientific®, New Jersey, USA). To quantify the nuclei, muscle fibers and capillary/fiber ratio, 10 images of randomized visual fields were used per animal (magnification of 400X). When measuring the capillary/fiber ratio, muscle fibers overlapping the upper and right margins were included in the count, while those overlapping the lower and left margin were excluded. Two trained evaluators individually performed the quantification and the mean values obtained were used<sup>18</sup>. For the muscle spindle measurements, images (magnification of 1000X) of the same muscle spindle were captured in 10 different cuts per animal. Standardized measurements were made of the area and diameter of the muscle spindle, mean cross-sectional area of intrafusal fibers, number of intrafusal fibers and thickness of the spindle capsule in the muscle spindle with the largest diameter.

Some of the other the histological sections of the EDL muscle was submitted to NADH-TR (Nicotinamide Adenine Dinucleotide - Tetrazolium Reductase) reaction

to analyze the oxidative and glycolytic metabolism of the muscle fibers (Pearse's technique<sup>19</sup>, modified by Dubowitz and Brooke<sup>20</sup>). The slides were dehydrated, diaphanized and mounted using Permount (Fisher Scientific, New Jersey, USA). Images of two visual fields (200x magnification) were used for the morphometric analyzes (cross-sectional area and counts of the three types of muscle fibers) of approximately 300 fibers per animal.

To quantify the percentage of intramuscular collagen, the remainder of the histological sections of the EDL muscle was stained with Masson's Trichrome. Three microscopic images from each animal were used in the analysis (magnification 200X). Once the images were captured, the percentage of collagen/total area was calculated.

### **Transmission electron microscopy (T.E.M.) study**

To visualize the ultrastructure of the muscle fibers from the EDL, the right antimere was removed and reduced to longitudinal fragments (approximately one mm wide) and immersed in glutaraldehyde (2.5%) for fixation. Subsequently, the samples were washed in 0.1M phosphate buffer, pH 7.3 (15 minutes) and post-fixed in 1% osmium tetroxide for two hours. After which, they were washed in distilled water, incubated in 0.5% uranyl acetate for 2 hours, dehydrated in acetone and soaked in a mixture of resin and 100% acetone (12 hours) for the subsequent formation of blocks. The desired fields were selected from semi-thin sections and ultra-thin sections were obtained using an ultramicrotome (Ultracut UCT, Leica®, Germany). The ultrathin sections were stained with a saturated solution of uranyl acetate and lead citrate. The material obtained was examined and photographed in a transmission electron microscope (CM100, Philips®, The Netherlands).

### **Evaluation of the NMJs**

For the study of the NMJs, the proximal part of the left antimere of the EDL muscle was removed and immersed in Karnovsky<sup>21</sup> at room temperature. Subsequently, the muscle was sectioned longitudinally into three or four slices with stainless steel blades for the nonspecific esterase reaction<sup>22</sup>. The sections were dehydrated, diaphanized and mounted with Permount (Fisher Scientific®, New Jersey, USA). Images of the NMJs (magnification of 200x) were obtained and

measurements of the area and largest and smallest diameters of 100 NMJs were taken for each animal.

### **Image analysis**

Images of the histological sections stained with HE, Masson's Trichrome staining and photo-documentation of the NMJs were taken using an Olympus Bx60 microscope coupled to an Olympus DP17 camera (Tokyo, Japan) with the aid of the DP Controller 3.2.1 276 program. Morphometric analyzes were performed using Image Pro Plus 6.0 software (Media Cybernetics, Maryland, USA). The analysis of the cross-sectional area and counts of the three types of muscle fibers (NADH-TR reaction) was conducted on a Primo Star, Zeiss (Oberkochen, Germany) microscope coupled to a camera (AxiocamERc5s) and a computer, measurements were performed with the aid of Axiovision Rel. 4.8 software (Carl Zeiss Microimaging Inc., Germany).

### **Statistical analysis**

The data obtained were statistically analyzed considering the results of the normality tests. Student's t-test was used when the data distribution was normal. In cases where the data distribution was not normal, the non-parametric Mann-Whitney statistical test was used. For the NADH-TR analysis, the two-way ANOVA test was used using the factors CP induction of and muscle fiber type, followed by Bonferroni's post-hoc test. Values of  $p < 0.05$  were considered significant. The statistical analysis was performed with the aid of GraphPad Prism 5.0 software (La Jolla, USA).

## **RESULTS**

### **Locomotor performance**

The animals from the CP group spent less time in locomotion compared to the CTL group ( $p < 0.001$ ) at 29 days of age, and at 45 days of age the difference between the groups persisted ( $p < 0.05$ ). No differences were observed between the CP and CTL groups regarding the number of quadrants crossed in the open field at 29 and 45 days of age (Table 1).

Regarding exploratory behavior, the frequency of rearing in the CP group was only lower when compared to the CTL group at 29 days of age ( $p < 0.01$ ). There were no differences between the experimental groups regarding the frequency of grooming behavior at either of the two evaluations.

### **Anthropometric variables**

At 48 days of age, the body weight of the animals in the CP group was 16% lower in relation to the CTL group ( $p < 0.001$ ). The animals in the CP group also presented a 16% reduction in weight ( $p < 0.01$ ) and a 15% reduction in EDL muscle length ( $p < 0.01$ ) when compared to the CTL group (Table 2).

### **Morphological and morphometric analysis of the muscle fibers**

The muscle fibers of the EDL muscle from the two experimental groups had a normal morphological aspect, regular diameter, a polygonal shape with rounded angles and peripheral nuclei in the subsarcolemmal position (Figures 1A and 1B). The fibers were arranged in fascicles surrounded by the perimysium, with each fiber being surrounded by endomysium (Figures 2A and 2B). Vessels and nerves were present in the connective tissue of the muscle. The muscle spindles in the EDL muscle were observed in the two studied groups and were found to have a normal organizational pattern, that is, smaller and thinner intrafusal fibers, surrounded by a connective tissue capsule (Figures 1C and 1D).

Regarding morphometry, there was an increase in the number of peripheral nuclei in the CP group compared to the CTL group ( $p = 0.034$ ), while the number of muscle fibers was similar between the studied groups (Figures 1A and 1B; Table 3). Thus, the core/fiber ratio was 27% higher in the CP group compared to the CTL group ( $p < 0.01$ ). There was also an increase of 23% in the capillary/fiber ratio (Table 3). In the CP group, the muscle spindle area and the mean cross-sectional area of the intrafusal fibers were 26% smaller when compared to the CTL group (Figures 1C and 1D; Table 3). However, there no significant difference between the groups in terms of the largest diameter of the muscle spindle, number of intrafusal fibers, or muscle spindle capsule thickness. Intramuscular collagen showed a 34% increase in the CP group compared to the CTL group ( $p = 0.009$ ; Figure 2C).



The histoenzymological analysis permitted the muscle fibers from the CP and CTL groups to be characterized as types I, IIA and IIB<sup>10</sup> (Figures 3A and 3B). There was a significant increase in the cross-sectional area of the type IIB fibers from the CP group compared to CTL (two-way ANOVA showed significant interaction effect ( $F_{(2,42)} = 3.35$ ;  $p = 0.04$ ), for the group ( $F_{(1,42)} = 6.88$ ;  $p = 0.01$ ) and for the fibers ( $F_{(2,42)} = 187$ ;  $p < 0.001$ ). Regarding the other fiber types, there were no differences between the groups (Figure 3C). Similarly, there was no significant difference between the groups in terms of count of the three identified muscle fiber types (Two-way ANOVA showed a significant effect for the fibers ( $F_{(2,42)} = 13.1$ ;  $p < 0.001$ ), whereas no effect was observed for the interaction ( $F_{(2,42)} = 1.88$ ;  $p = 0.16$ ) and for the group ( $F_{(1,42)} = 0.11$ ;  $p = 0.74$ ) (Figure 3D).

### **Ultrastructural analysis of the EDL muscle**

The morphology of the EDL muscle from the CTL group exhibited sarcoplasm with the presence of well-defined myofibrils and an organized Z-line (Figure 4A). In the animals from the CP group, there was dissolution and disorganization of the Z-line in several regions ( $p < 0.05$ ) and rarefied or loosely arranged myofibrils ( $p < 0.001$ , Figures 4B and 4C) were observed.

### **Morphological and morphometric analysis of NMJs**

The NMJs from the CP and CTL groups were polymorphic, round, oval and elliptical in shape (Figures 5A and 5B). The morphometric analysis showed an increase in the area (22%,  $p < 0.001$ , Figure 5C) and in the larger diameter (11%,  $p < 0.05$ ) of the NMJs from the CP group compared to the CTL group (Figure 5D). There was no significant difference between the groups studied in relation to the smallest diameter of the NMJs (Figure 5E).

## **DISCUSSION**

In the present study, the animals from the CP group spent less time locomotion during the open field test when compared to the CTL group at 29 and 45 days of age. There was no improvement in this parameter even after the removal of the sensorimotor restriction, which took place at 30 days of age. Regarding the

number of quadrants crossed by the animals during that test, the CP and CTL groups were similar at 29 and 45 days of age. These results show the animals in the CP group moved for less time, but appeared to have traveled a distance similar to that of the CTL animals. Sensorimotor restraint causes intrinsic muscle disruption due to disuse<sup>4</sup> and animals submitted to this procedure have difficulty discharging the plantar weight during the support phase, which may compromise gait and other motor skills<sup>15</sup>. However, the result might be related to the fact the animals from the CP group compensated for their deficits by greater use of the thoracic limbs. When using LPS injections combined with perinatal anoxia, Stigger *et al.*<sup>23</sup>, also found no difference in the distance covered in the open field test at 29 days of age. Grooming frequency was also similar between the CP and CTL groups at both evaluations. Although LPS injections and perinatal anoxia are known to be able to cause damage to the white matter and disorganization of M1<sup>15,24,25</sup>, these two insults may not have affected thoracic limb motor control in the CP group. As for the number of rearings, a behavior that requires strength and control of the pelvic limbs, there was a reduction in the CP group when compared to the CTL group at 29 days. Thus, sensorimotor restriction would seem to play a fundamental role in inducing motor alterations in the hind limbs. Spontaneous motor activity is known to be essential for the development of the corticospinal tract<sup>26</sup>. Motor experiments reinforce and refine synaptic connectivity, favor myelination of the corticospinal tract and maturation of the motor unit and reflex circuits. Interventions that impair the performance of movements during the development of locomotion, such as sensorimotor restraint, may disturb the establishment of connections within the motor circuit<sup>26</sup>, leading to functional impairment.

The body weight of the animals from the CP group was significantly lower than that of the CTL group. In humans, low birth weight is one of the main risk factors associated with CP<sup>27,28</sup>. Marques *et al.*<sup>29</sup>, using LPS injections, perinatal anoxia and sensorimotor restriction to induce CP, also observed reduced body weight in the animals and attributed the finding to a decrease in bone mineral density due to lack of weight discharge. In this study, a reduction in the length of the EDL muscle was also observed in the CP group. Longitudinal muscle growth occurs in the first four to six postnatal weeks in rats. Radial muscle growth occurs simultaneously and lasts a further 10 weeks<sup>30</sup>. The lack of longitudinal growth of skeletal muscle in patients with CP leads to muscle contractures, long bone twitches and early joint degeneration<sup>5</sup>.

Again, this animal model of CP reproduced one of the characteristic clinical findings of this pathology, muscular shortening. To the best of our knowledge, this is the first description of these parameters using such an experimental CP model.

Striated skeletal muscle is a highly dynamic tissue that can alter its morphological, metabolic and functional characteristics in response to changes in the quantity and/or pattern of neuromuscular activity<sup>31</sup>. In the present study, there was an increase in the number of peripheral nuclei and in the core/fiber ratio in the CP group. Muscle fibers that have a greater number of nuclei generally have a larger cross-sectional area, but in certain circumstances, these parameters may change independently of one another<sup>32</sup>. The CP group was also found to have a higher capillary/muscle fiber ratio associated with hypertrophy of type IIB fibers in the EDL muscle. Increased capillary density, resistance, and hypertrophy of muscle fibers are some of the changes seen in target muscles of continuous muscular activation due to spasticity<sup>33,34</sup>. Although the sensorimotor restriction model used in this study is considered of disuse, the characteristics found in the EDL muscle of the CP group are compatible with those observed in spastic muscles.

In this study, an increase in intramuscular collagen was observed. Neuronal activity regulates the synthesis of collagen and in spastic muscles the neuronal stimulation is intensified<sup>35</sup>. Gagliano *et al* (2013)<sup>36</sup> observed that patients with spastic CP also have increased collagen in the tendons. These muscular alterations lead to muscle stiffness and reduced function<sup>4</sup>. Spasticity-induced fibrosis directly limits muscle length growth<sup>35</sup>, which together forms a mechanical barrier to muscle regeneration<sup>37</sup>. Additional factors that may contribute to muscle rigidity are the organization of collagen, the distribution of collagen types and the proteoglycan content<sup>38</sup>.

This is the first time the characteristics of muscle with a predominance of type II fibers following the induction of this animal model of CP have been observed. In an earlier study, Marcuzzo *et al.*<sup>39</sup> showed that the sensorimotor restriction alone or associated with perinatal anoxia causes atrophy of the soleus muscle of rats, which was improved after treadmill training. Stigger *et al.*<sup>39</sup> noted a reduction in the cross-sectional area of the *soleus* and *anterior tibial* muscle fibers using the same CP model. The predominance of fibers within a muscle will cause it to have different biochemical and structural properties<sup>40</sup>, which promote varied responses to certain insults<sup>41</sup>.

Regarding the muscle spindles, the absence of weight discharge is known to be able to reduce the cross-section area of the intrafusal fibers, decrease the diameter of the equatorial region and fragment the nerve endings<sup>42</sup>. In the present study, there was a decrease in the muscle spindle area and the cross-sectional area of the intrafusal fibers in the CP group. Apparently, the period between removal of the sensorimotor restraint and the euthanasia of the animals was insufficient to repair the muscle spindle structure, although the intrafusal fibers presented high concentrations of satellite cells and a smaller myonuclear domain (amount of cytoplasm supported by a single nucleus), which favor growth, regeneration and repair<sup>42</sup>.

The ultrastructural study of the EDL muscle showed alterations such as myofibrillar disruption and Z-line disorganization and dissolution in the animals from the CP group. Studies using electron microscopy in animal models of CP are scarce and are generally conducted through biopsies of individuals with this pathology. Patients with myofibrillar myopathies exhibit ultrastructural alterations that are typically focal. Some regions contain normal sarcomeres alternating with areas of pronounced myofibrillar disruption<sup>42</sup>. This animal model reproduced focal ultrastructural changes similar to those found in patients with CP. According to Marbini *et al.* (2002)<sup>34</sup>, myofibrillar disruption is found in all cases, which is associated with Z-line disorganization and a consequent loss of the striation that is characteristic of the skeletal muscle.

The animals from the CP group presented an increase in the area and in the largest diameter of the NMJs when compared to the CTL group. NMJs are structures that can remodel themselves according to the functional demands<sup>45</sup>. Conditions such as disuse, neuromuscular disorders and aging lead to muscle weakness, causing NMJs to lose functionality in the most affected regions<sup>46</sup>. In this study, the disuse caused by the sensorimotor restriction may have caused the longitudinal lengthening of the nerve terminals in order to reinforce synaptic transmission and maintain muscle function<sup>47</sup>.

## **CONCLUSION**

The association of LPS injections, perinatal anoxia and sensorimotor restraint produced lasting effects on the function and structure of the muscular system, as

shown by the reduction in rearing frequency and in muscle length. There were increases in the nuclei/fiber ratio, capillary/fiber ratio, type IIB fiber muscle hypertrophy and intramuscular collagen, which are findings commonly found in patients with spastic CP. The morphological alterations found in the muscle spindle may affect posture maintenance and movement coordination. The ultrastructural study of the EDL muscle showed alterations similar to those found in biopsies of patients with CP. However, the alterations to the NMJs caused by the animal model of CP constitute new discoveries, which require further investigation.

This animal model proved to be a useful means to understand the pathophysiology of this clinical condition. It is suggested that new studies be performed with evaluations at different periods, that is, during sensorimotor restriction and soon after its removal. The need for such studies became evident due to the fact that immobilization in the developmental period of locomotion aggravated the repercussions of the clinical condition. Given this, this experimental model could be an important tool to check the efficacy of early-start rehabilitation programs.

## **ACKNOWLEDGEMENTS**

We are grateful to UNIOESTE - Campus of Cascavel for the assistance provided at all stages of the experiment and the Coordination of Improvement of Higher Education Personnel (CAPES) for the postgraduate scholarship.

## **REFERENCES**

- 1 - Rotta NT. Paralisia cerebral, novas perspectivas terapêuticas. J. Pediatr. 2002; 78(Supl.1): S48-S54.
- 2 - Mancini MC, Fiúza PM, Rebelo JM, Magalhães LC, Coelho ZAC, Paixão ML, Gontijo APB, Fonseca ST. Comparação do desempenho de atividades funcionais em crianças com desenvolvimento normal e crianças com paralisia cerebral. Arq. Neuropsiquiatr. 2002; 60 (2-B): 446-452.

- 3 - Rosenbaum P, Bax M, Goldstein M, Paneth N, Jacobsson B, Leviton A, Dan B. Proposed definition and classification of cerebral palsy, April 2005. *Dev. Med. Child Neurol.* 2005; 47: 571-576.
- 4 - Coq JO, Strata F, Russier M, Safadi FF, Merzenich MM, Byl NN, Barbe MF. Impact of neonatal asphyxia and hind limb immobilization on musculoskeletal tissues and S1 map organization: Implications for cerebral palsy. *Exp. Neurol.* 2008; 210: 95-108.
- 5 - Graham HK, Selber P. Musculoskeletal aspects of cerebral palsy. *J. Bone Joint Surg.* 2003; 85-B (2): 157-166.
- 6 - Robinson KG, Mendonça JL, Militar JL, Theroux MC, Dabney KW, Shah SA, Miller F, Akins RE. Disruption of Basal Lamina Components in Neuromotor Synapses of Children with Spastic Quadriplegic Cerebral Palsy. *Plos One.* 2013; 8 (8): 2-16.
- 7 - Wu H, Xiong WC, Mei L. To build a synapse: signaling pathways in neuromuscular junction assembly. *Development.* 2010; 137: 1017-1033.
- 8 - Schiaffino S, Reggiani C. Fibers types in mammalian skeletal muscles. *Physiol. Rev.* 2011; 91: 1447-1531.
- 9 - Zvaritch E, MacLennan DH. Muscle spindles exhibit core lesions and extensive degeneration of intrafusal fibers in the Ryr1(I4895T/wt) mouse model of core myopathy. *Biochem Biophys Res Commun.* 2015; 460 (1): 34-39.
- 10 - Yoshimura A, Toyoda Y, Murakami T, Yoshizato H, Ando Y, Fujitsuka, N. Glycogen depletion in intrafusal fibres in rats during short-duration high-intensity treadmill running. *Acta Physiol. Scand.* 2005; 185 (1): 41-50.
- 11 - Khazipov R, Sirota A, Leinekugel X, Holmes GL, Ben-ari Y, Buzsáki G. Early motor activity drives spindle bursts in the developing somatosensory cortex. *Nature.* 2004; 432 (9): 758-761.
- 12 - Delcour M, Russier M, Xin DL, Massicotte VS, Barbe MF, Coq JO. Mild musculoskeletal and locomotor alterations in adult rats with white matter injury following prenatal ischemia. *Int. J. Devl Neuroscience.* 2011; 29: 593-607.

13 - Lubics A, Reelodi D, Tamás A, Kiss P, Szalai M, Szalontay L, Lengvari I. Neurological reflexes and early motor behavior in rats subjected to neonatal hypoxic-ischemic injury. *Beh. Brain Res.* 2005; 157: 157-165.

14 - Marcuzzo S, Dutra MF, Stigger F, Nascimento PS, Ilha J, Kalil-Gaspar PI, Achaval M. Different effects of anoxia and hind-limb immobilization on sensorimotor development and cell numbers in the somatosensory cortex in rats. *Brain Dev.* 2010; 32: 323-331.

15 - Strata F, Coq JO, Byl N, Merzenich MM. Effects of sensorimotor restriction and anoxia on gait and motor cortex organization: implications for a rodent model of cerebral palsy. *Neuroscience.* 2004; 129: 141-156.

16 - Stigger F, Felizzola AL, Kronbauer GA, Couto GK, Achaval M, Marcuzzo S. Effects of fetal exposure to lipopolysaccharide, perinatal anoxia and sensorimotor restriction on motor skills and musculoskeletal tissue: implications for an animal model of cerebral palsy. *Exp. Neurol.* 2011; 228 (2): 183-191.

17 - Junqueira LC, Junqueira LMM. Técnicas básicas de citologia e histologia. São Paulo: Universidade de São Paulo, 1983, p.123.

18 - Fernandes T, Roque FR, Magalhães FC, Carmo EC, Oliveira EM. O treinamento físico aeróbico corrige a rarefação capilar e as alterações nas proporções dos tipos de fibras muscular esquelética em ratos espontaneamente hipertensos. *Rev. Bras. Med. Esporte.* 2012; 18 (4): 267-272.

19 - Pearse AGE. *Histochemistry: theoretical and applied.* 3. ed. Baltimore: Williams e Wilkins, 1972. p.921-961.

20 - Dubowitz V, Brooke M. *Muscle biopsy: a modern approach.* London: Saunders, 1973. p.475.

21 - Karnovsky MJ. A formaldehyde-glutaraldehyde fixative of high osmolarity for use in electron microscopy. *J. Cell. Biol.* 1965; 27: 137-138.

22 - Lehrer GM, Ornstein L. A diazo coupling method for the electron microscopic localization of cholinesterase. *Biophys. Biochem. Cytol.* 1959; 6 (3): 399-419.

23 - Stigger F, Lovatel G, Marques M, Bertoldi K, Moysés F, Elsner V, Siqueira IR, Achaval M, Marcuzzo S. Inflammatory response and oxidative stress in developing rat brain and its consequences on motor behavior following maternal administration of LPS and perinatal anoxia. *Int. J. Devl. Neurosci.* 2013; 31: 820-827.

- 24 - Dammann O, Durum S, Leviton A. Do white cells matter in white matter damage? *Trends NeuroSci.* 2001; 24 (6): 320-324.
- 25 - Wang X, Rousset CI, Hagberg H, Mallard C. Lipopolysaccharide-induced inflammation and perinatal brain injury. *Semin. Fetal Neonatal Med.* 2006; 11 (5): 343-353.
- 26 - Clowry GJ. The dependence of spinal cord development on corticospinal input and its significance in understanding and treating spastic cerebral palsy. *Neurosci. Biobehav. Rev.* 2007; 31: 1114-1124.
- 27 - Johnston MV, Hoon Junior AH. Cerebral Palsy. *Neuromol. Med.* 2006; 8: 435-450.
- 28 - Colver A, Fairhurst C, Pharoah POD. Cerebral palsy. *Lancet.* 2014; 383 (5):1240-1249.
- 29 - Marques MR, Stigger F, Segabinazi E, Augustin OA, Barbosa S, Piazza FV, Achaval M, Marcuzzo S. Beneficial effects of early environmental enrichment on motor development and spinal cord plasticity in a rat model of cerebral palsy. *Behav Brain Res.* 2014; 263: 149-157.
- 30 - Dayanidhi S, Lieber RL. Skeletal muscle satellite cells: Mediators of muscle growth during development and implications for developmental disorders. *Muscle Nerve.* 2014; 50(5): 723-732.
- 31 - Allen DL, Roy RR, Edgerton VR. Myonuclear domains in muscle adaptation and disease. *Muscle Nerve.* 1999; 22 (10): 1350-1360.
- 32 - Roy RR, Monke SR, Allen DL, Edgerton VR. Modulation of myonuclear number in functionally overloaded and exercised rat plantaris fibers. *J. Appl. Physiol.* 1999; 87 (2): 634-642.
- 33 - Foran JRH, Steinman S, Barash I, Chambers HG, Lieber RL. Structural and mechanical alterations in spastic skeletal muscle. *Dev. Med. Child. Neurol.* 2005; 43: 314-320.



- 34 - Marbini A, Ferrari A, Cioni G, Bellanova MF, Fusco C, Gemignani F. Immunohistochemical study of muscle biopsy in children with cerebral palsy. *Brain Dev.* 2002; 24: 63-66.
- 35- Booth CM, Cortina-Borja MJF, Theologis TN. Collagen accumulation in muscles of children with cerebral palsy and correlation with severity of spasticity. *Dev. Med. Child Neurol.* 2001; 43: 314-320.
- 36 - Gagliano N, Menon A, Martinelli C, Pettinari L, Panou A, Milzani A, Dalle-Donne I, Portinaro NM. Tendon structure and extracellular matrix components are affected by spasticity in cerebral palsy patients. *Muscles Ligaments Tendons J.* 2013; 3 (1): 42-50.
- 37- Chen X, Li Y. Role of matrix metalloproteinases in skeletal muscle: migration, differentiation, regeneration and fibrosis. *Cell Adh Migr.* 2009; 3: 337-341.
- 38- Smith LR, Lee KS, Ward SR, Chambers HG, Lieber RL. Hamstring contractures in children with spastic cerebral palsy result from a stiffer extracellular matrix and increased in vivo sarcomere length. *J Physiol.* 2011; 589 (10): 2625-2639.
- 39 - Marcuzzo S, Dutra MF, Stigger F, Nascimento PS, Ilha J, Kalil- Gaspar PI, Achaval M. Beneficial effects of treadmill training in a cerebral palsy-like rodent model: Walking pattern and soleus quantitative histology. *Brain Res.* 2008; 1222: 129-140.
- 40 - Almeida- Silveira MI, Pérot C, Pousson M, Goubel F. Effects of stretch-shortening cycle training on mechanical properties and fibre type transition in the rat soleus muscle. *Pflugers Arch. Eur. J. Physiol.* 1994; 427: 289-294.
- 41 - Mercier C, Jobin J, Lépine C, Simard C. Effects of hindlimb suspension on contractile properties of young and old rat muscles and the impact of electrical stimulation on the recovery process. *Mech. Ageing Dev.* 1999; 106: 305-320.
- 42 - Zhu Y, Fan X, Li X, Wu S, Zhang H, Yu L. Effect of hindlimb unloading on resting intracellular calcium in intrafusal fibers and ramp-and-hold stretch-evoked responsiveness of soleus muscle spindles in conscious rats. *Neurosci. Lett.* 2008; 442 (3): 169-173.
- 43 - Kirkpatrick LJ, Allouh MZ, Nightingale CN, Devon HG, Yablonka-Reuveni Z, Rosser BWC. Pax7 Shows Higher Satellite Cell Frequencies and Concentrations Within Intrafusal Fibers of Muscle Spindles. *J. Histochem. Cytochem.* 2008; 56: 831-840.

44 - Claeys KG, Fardeau M, Schroder R, Suominen T, Tolksdorf K, Behin A, Dubourg O, Eymard B, Maisonobe T, Stojkovic T, Faulkner G, Richard P, Vicard P, Udd B, Voit T, Stoltenburg G. Electron microscopy in myofibrillar myopathies reveals clues to the mutated gene. *Neuromuscul. Disord.* 2008; 18: 656-666.

45 - Pratt SJP, Shah SB, Ward CW, Inacio MP, Stains JP, Lovering RM. Effects of *in vivo* injury on the neuromuscular junction in healthy and dystrophic muscles. *J. Physiol.* 2013; 591 (2): 559-570.

46 - Rudolf R, Deschenes MR, Sandri M. Neuromuscular junction degeneration in muscle wasting. *Curr. Opin. Clin. Nutr. Metab. Care.* 2016; 19 (0): 1-5.

47 - Fahim MA, Robbins N. Remodelling of the neuromuscular junction after subtotal disuse. *Brain Research.* 1986; 383: 353-356.

**Table 1.** Locomotor variables of the animals from the CTL and CP groups evaluated in the open field at 29 and 45 days of age.

<b>Variables</b>	<b>CTL</b>	<b>CP</b>	<b>CTL</b>	<b>CP</b>
<b>(n = 10)</b>	<b>P29</b>	<b>P29</b>	<b>P45</b>	<b>P45</b>
Locomotion time (seconds)	94.1 ± 15.8	55.9 ± 24.2***	67.3 ± 16.8	49.2 ± 21.6*
Number of quadrant crossings	96.1 ± 22.1	85.2 ± 35.9	72.2 ± 30.6	69.9 ± 39.2
Grooming frequency	2.5 ± 1.0	2.7 ± 0.8	2.3 ± 0.9	3.1 ± 1.3
Number of rearings	37.0 ± 7.6	21.0 ± 12.5**	21.3 ± 12.6	22.3 ± 12.3

Values expressed as mean ± standard deviation. Grooming frequency: Mann Whitney test. Other parameters: Student's *t*-test. \* Represents  $p < 0.05$ , \*\* Represents  $p < 0.01$ , \*\*\* Represents  $p < 0.001$ .

**Table 2.** Body weight and EDL muscle weight and length in rats at 48 days of age.


<b>Variables (n = 10)</b>	<b>CTL</b>	<b>CP</b>
Body weight (g)	197 ± 6.8	165 ± 17.2***
Muscle weight (g)	0.08 ± 0.01	0.07 ± 0.01**
Muscle length (mm)	21.4 ± 3.1	18.2 ± 2.1**

Values expressed as mean ± standard deviation. Animal weight: Mann Whitney test. Other parameters: Student's *t*-test. \*\* Represents  $p < 0.01$ , \*\*\* Represents  $p < 0.001$ .


**Table 3.** Morphometry of the EDL muscle and muscle spindles from the CTL and CP groups at 48 days of age.

Variables (n = 8)	CTL	CP
Number of peripheral nuclei	869.3 ± 82.6	1060 ± 214.7*
Number of muscular fibers	492.4 ± 60.4	472.9 ± 79.8
Nuclei/fiber	1.8 ± 0.3	2.2 ± 0.3**
Capillary/fiber	2.2 ± 0.2	2.7 ± 0.3**
Largest diameter of muscle spindles (µm)	74.5 ± 16.1	82.5 ± 40.3
Cross-sectional area of muscle spindles (µm <sup>2</sup> )	3443 ± 1264	2541 ± 1603*
Number of intrafusal fibers	4.1 ± 0.4	4.3 ± 0.7
Cross-sectional area of intrafusal fibers (µm <sup>2</sup> )	182.4 ± 56.3	135.3 ± 35.2*
Muscle spindle capsule thickness (µm)	20.3 ± 13.4	19.4 ± 15.2


Values expressed as mean ± standard deviation. \* Represents p <0.05. \*\* Represents p <0.01. Number of peripheral nuclei, Number of muscle fibers, Nuclei/fiber, Capillary/fiber and Largest diameter of muscle spindles: Student *t*-test. Other parameters: Mann Whitney test.



**Figure 1** - Photomicrographs of EDL muscle fibers from Wistar rats at 48 days of age. Cross section, HE staining. CTL (**A** and **C**) and CP (**B** and **D**) groups. **A** and **B**: Note the perimysium (thick arrows), endomysium (long arrows). **C** and **D**: Note the peripheral nuclei (white arrows), muscle spindle capsule (thick arrows), intrafusal fibers (arrow heads) and capillaries (thin arrows).




**Figure 2** - Photomicrographs of the collagen quantification in the EDL muscle of Wistar rats at 48 days of age. Longitudinal section, Masson trichrome. **A** and **B**: Note the perimysium (short arrow) and endomysium (long arrow) in the animals from the CTL and CP groups, respectively. **C**: Percentage of the intramuscular collagen of the animals from the CTL and CP groups. Values expressed as mean  $\pm$  standard deviation. \*\*Represents  $p < 0.01$ ; Student's  $t$ -test.




**Figure 3** - Photomicrographs of the NADH-TR reaction in the EDL muscle fibers of Wistar rats at 48 days of age. Cross section. **A** and **B**: Morphology of the different types of muscle fibers in the CTL and CP groups, respectively. Fibers with small diameter (I), intermediate diameter (IIA) and large diameter (IIB). **C**: Cross-sectional area of the different types of muscle fibers observed in the EDL muscle in rats from the CP and CTL groups. **D**: Number of muscle fibers of types I, IIA and IIB observed in the EDL muscle of rats from the CP and CTL groups. Values expressed as mean  $\pm$  standard deviation. Two-way ANOVA, *post-hoc* Bonferroni test.





<b>C</b>	<b>Observations</b>	<b>CTL Group</b>	<b>CP Group</b>
	Z Line disorganization (%)	18,3 ± 10,4	67,25 ± 8,3***
	Z line dissolution (%)	5,0 ± 5,0	23,8 ± 14,7*
	Myofibrillar disruption (%)	9,0 ± 9,6	25,8 ± 8,5*

**Figure 4** - Transmission electro-micrographs of 48-day-old rat EDL muscle in longitudinal section. **A:** CTL Group - Organized myofibrils (short arrow) and alignment of the Z line (long arrow). **B:** CP Group - Myofibrils, sparse or loosely arranged (short arrow), disorganization (long arrow) and dissolution of the Z line (arrowhead). Bar = 1μm. **C:** Values expressed as mean ± standard deviation. Z-line dissolution: Mann Whitney test. Other parameters: Student's *t*-test.



**Figure 5** - Photomicrographs of the NMJs observed in the EDL muscle of Wistar rats at 48 days of age. Longitudinal section, Non-specific esterase reaction. **A** and **B**: Morphological characteristics of the NMJs of the animals from the CTL and CP groups. **C**, **D** and **E**: Area, largest diameter and smallest diameter of the NMJs of the animals from the CTL and CP groups, respectively. Values expressed as mean  $\pm$  standard deviation. \*\*\*Represents  $p < 0.001$ ; \*Represents  $p < 0.05$ . Smallest diameter of NMJs: Mann Whitney test. Other parameters: Student's  $t$ -test.

## ANEXO A:




### Certificado Experimental no Uso de Animais em Pesquisa Nº 24/16 - CEUA

Certificamos que a proposta intitulada "Implicações de um modelo de paralisia cerebral sobre a função motora, cognitiva e morfologia do sistema nervoso e muscular", registrar-se com o número "02/14", sob a responsabilidade de "Lígia A. Centenaro", que envolve a produção, manutenção ou utilização de animais pertencentes ao filo Chordata, subfilo Vertebrata (exceto humanos), para fins de pesquisa científica (ou ensino) – encontra-se de acordo com os preceitos da Lei nº 11.794, de 8 de outubro de 2008, do decreto nº 6.899, de 15 de julho de 2009, e com as normas editadas pelo Conselho Nacional de Controle de Experimentação Animal (CONCEA), e foi aprovado pelo COMITÊ DE ÉTICA NO USO DE ANIMAIS (CEUA) DA UNIVERSIDADE ESTADUAL DO OESTE DO PARANÁ (UNIOESTE), em reunião de 13/05/2016.

ingresso da Unioeste - pppg/2016

Finalidade	Pesquisa Científica
Vigência da autorização	15/09/2014 – 31/08/2014
Espécie/linhagem/raça	Rato/Wistar
Nº de animais	34 Machos e 32 Fêmeas
Peso/idade	42=250g/60 dias 24=5g/Neonatos
Sexo	Masculino/Feminino
Origem	Biotério Central da Unioeste

  
**Prof. Dirceu Baumgartner**  
 Coordenadora Suplente do CEUA UNIOESTE  
 Portaria nº 3730/2016

## **ANEXO B:**

### **Normas das revistas científicas**

## American Journal of Obstetrics & Gynecology

### Article Types

- Every submission must include a title page with a disclosure statement and a signed statement of authorship form. This requirement applies to ALL article types listed in the following section; including letters, replies, mixed media, etc.
- The editors encourage the supplementary use of multimedia components such as PowerPoint, additional images, or video clips. Color figures and images are free.

### *Original Research*

Manuscripts are limited to 3000 words of main text (not counting the title page, abstract, condensation, acknowledgements, references, tables, figures, and legends).

All authors must meet authorship criteria (see Named Authors and Contributors).

*Systematic review and metaanalysis studies: please refer to Systematic Reviews.*

Research articles must be accompanied by a structured abstract between 250 and 500 words, accompanied by as many alphabetized key words or short phrases as needed for indexing.

**Structured Abstract** - applies to Original Research and Reports of Major Impact

Between 250 and 500 words with the following required headings:

1. **Background:** an explanation of the basis of the study (NOTE: This is a NEW heading)
2. **Objective(s):** the purpose of the study (hypothesis being tested)
3. **Study Design:** the setting for the study, subjects (number and type), treatment or intervention, and type(s) of statistical analysis used
4. **Results:** the outcome(s) of the study and, if appropriate, their statistical significance
5. **Conclusion(s):** overall significance of the results

The type(s) of non-human animals or other species used in an investigation must be named in the Title, Abstract, and Materials and Methods sections of the manuscript.

Each original research article is published in 2 formats: 1) in the printed journal: in an

abbreviated form, that includes the abstract and 1 figure or table, and 2) in full on the Journal website ([ajog.org](http://ajog.org)), where the abstract also appears. The full length article is the official version and is linked to search engines. (Note: Expert Reviews, Systematic Reviews, Clinical Opinion, Call to Action, Viewpoint, and Point/Counterpoint are published in full in both the print and online versions.)

The full-length article becomes available online for citation before the print issue containing the abstract and accompanying material. Impact Factors and other citation indices are based on the full-length online article.

### *Translational Science*

Translational science is typically presented in the form of an original research manuscript; however, the only type of non-clinical research considered must be translational in nature and contain biological implications for obstetrics and gynecology. Basic science without direct clinical relevance will not be considered; please see Editorial Policies for examples.

### *Reports of Major Impact*

Authors who believe their original research article has the potential for affecting clinical practice in a major way or is otherwise of urgent importance may submit the manuscript under this category. The editors, in consultation with experts in the area addressed in the article, will assess the likely impact of the article and notify the authors whether it is being considered for this category or as a regular original research manuscript.

Articles accepted as Reports of Major Impact are reviewed and published as rapidly as possible. The authors are to follow the format for original research articles. As with any article, concern about any potential conflict arising from the timing of publication relative to a presentation at a scientific meeting may be communicated to the editors, who will, at the authors' request, delay publication until the paper has been presented.

### *Reviews*

#### **Expert Reviews**

These invited articles provide concise reviews on a topic in which the author has expertise. The manuscript should be comprehensive and balanced, but not exhaustive. Expert Reviews must be evidence based but may include some expert opinion and recommendations. The goal is to provide a concise update on the state of the art and guidelines for clinical care.

Expert Reviews are limited to 3500 words of main text (not counting the title page, abstract, condensation, acknowledgments, references, tables, legends, and figures). An unstructured abstract (1 paragraph, no categories) of no more than 350 words and as many alphabetized key words or short phrases as needed for indexing must be provided.

Subheadings to separate and identify sections of text should be unique to the topic; the 4 prescribed subheadings required for research articles do not apply. To prevent such subheadings from occupying many lines on a page, they should be as short as possible, not exceeding approximately 6 words, and preferably 1 to 4 words.

The full-length article appears both in print and on the Journal website.

### **Systematic Reviews**

Each article in this category provides a comprehensive and exhaustive systematic review of the literature related to the topic, collating all relevant evidence meeting pre-specified eligibility criteria. Systematic reviews may not be combined with other manuscript types.

Systematic reviews must include a clearly stated set of objectives with reproducible methodology, a systematic search, eligibility criteria for selecting studies, assessment of study quality (risk of bias), an assessment of the validity of the findings and systematic synthesis of these findings. Metaanalysis, the use of statistical techniques to combine and summarize results across studies, may or may not be contained within a systematic review.

Authors must adhere to the PRISMA and MOOSE guidelines (for guidance see Editorial Policies).

Systematic Reviews are limited to 5000 words of main text (not counting the title page, abstract, condensation, acknowledgments, references, tables, legends, and figures). Include a structured abstract containing no more than 350 words and as many alphabetized key words or short phrases as needed for indexing.

**Title:** The title should identify the report as systematic review or metaanalysis.

**Abstract:** Include a structured summary according to PRISMA guidelines with the following headings:

- Objective
- Data sources (including years searched)
- Study eligibility criteria (study design, populations, and interventions [if applicable])
- Study appraisal and synthesis methods
- Results
- Conclusions

**Main text:** Headings and subheadings in the main text should include the following; note that subheadings may be modified to best represent the specific report.

- Introduction (rationale, explain impetus for Review)
- Objective(s)
- Methods
  - Eligibility criteria, information sources, search strategy
  - Study selection
  - Data extraction
  - Assessment of risk of bias
  - Data synthesis
- Results
  - Study selection
  - Study characteristics
  - Risk of bias of included studies
  - Synthesis of results
- Comment
  - Main findings
  - Strengths and limitations
  - Comparison with existing literature
  - Conclusions and Implications

The full-length article appears both in print and on the Journal website.

### *Clinical Opinion*

A Clinical Opinion paper presents a balanced, evidence-based discussion of a clinical issue pertinent to obstetricians and gynecologists. The paper may address an emerging or controversial topic or bring attention to a topic of increasing clinical significance. Opinions rendered must be based on an interpretation of available evidence.

*Not appropriate for this category:* 1) a review of an extensively researched subject. Submit as a Systematic Review. 2) an essay about issues for which minimal data exist, such as certain clinical, ethical, educational, practice, and research issues. Submit as a Viewpoint paper.

A Clinical Opinion paper is limited to 3000 words of main text (not counting the title page, abstract, condensation, acknowledgments, references, tables, legends, and figures). An unstructured abstract (1 paragraph; no headings) of no more than 350 words and as many alphabetized key words or short phrases as needed for indexing must be provided.



Subheadings to separate and identify sections of the text should be unique to the topic; the 4 prescribed categories required for research articles do not apply. To prevent such subheadings from occupying many lines on a page, they should be as short as possible, not exceeding approximately 6 words and preferably 1 to 4 words.

The full-length article appears both in print and on the Journal website.

### *Special Report*

A Special Report is released by a consensus committee, working group, task force, or similar group, or summarizes the findings of an important meeting.

Include a condensation, an unstructured abstract (1 paragraph, no subheadings) of no more than 350 words, and as many alphabetized key words or short phrases as needed for indexing.

Subheadings to separate and identify sections of the text should be unique to the topic; the 4 prescribed categories required for research articles do not apply. To prevent such subheadings from occupying too many lines on a page, they should be as short as possible, not exceeding approximately 6 words and preferably 1 to 4 words.

The full-length article appears both in print and on the Journal website.

### *Viewpoint*

Viewpoint articles are well-founded, scholarly pieces that address a scientific, ethical, academic, or practice-related topic in women's health. The article should be balanced and based on a critical analysis of the literature. Viewpoint articles are intended to stimulate discussion.

Viewpoint articles are limited to 1500 words of main text (not counting the title page, condensation, abstract, acknowledgments, references, tables, legends, and figures).

Include a condensation, an unstructured abstract (1 paragraph, no subheadings) of no more than 350 words, and as many alphabetized key words or short phrases as needed for indexing.

The full-length article appears both in print and on the Journal website.

### *Point/Counterpoint*

Point/Counterpoint presents 2 essays of differing views about a controversial issue of interest to AJOG's readers. These articles are generally solicited by the editors, but readers are encouraged to suggest topics for this section.

Each essay is limited to 1500 words of main text (not counting the title page, condensation, abstract, acknowledgments, references, tables, legends, and figures).

Include a condensation, an unstructured abstract (1 paragraph, no subheadings) of no more than 350 words, and as many alphabetized key words or short phrases as needed for indexing.

Subheadings to separate and identify sections of the text should be unique to the topic; the 4 prescribed categories required for research articles do not apply. To prevent such subheadings from occupying too many lines on a page, they should be as short as possible, not exceeding approximately 6 words, and preferably 1 to 4 words.

The essays appear in full, both in print and on the Journal website.

### *Call to Action*

Call to Action is a topical piece highlighting a problem related to a clinical, research, social, ethical, political, or economic issue pertinent to obstetricians and gynecologists and a suggested solution to that problem. Accordingly, the author must include a suggested corrective action; describing the problem alone is not sufficient.

Call to Action articles are limited to 2000 words of text (not counting the title page, condensation, abstract, acknowledgements, references, tables, legends, and figures).

Include a condensation, an unstructured abstract (1 paragraph, no subheadings) of no more than 350 words, and as many alphabetized key words or short phrases as needed for indexing. The main text must include: 1) "The Problem:," a one-sentence statement of the problem being presented; 2) "A Solution:," a one-sentence summary of the proposed solution; and 3) the presentation.

The full-length article appears both in print and on the Journal website.

### *Case Report*

The Journal no longer publishes Case Reports.

### *Editorials*

Editorials are written or solicited by the editors. Spontaneous submissions are not considered for publication.

### *Images in Obstetrics; Images in Gynecology*

An Interesting image of clinical significance, such as a clinical photograph or evidence of a diagnostic test (ultrasound scan, MRI film, slide, photomicrograph,

DNA blot, or similar), is accompanied by a case description of no more than 350 words (not counting the title page, acknowledgements, references, tables, legends, and figures). The manuscript must include:

1. Condensation: a 1-sentence condensation of the paper, consisting of no more than 25 words, to be placed in the Table of Contents.
2. Case Notes: a brief case presentation (under the heading "Case Notes") with introduction of relevant image(s) accompanied either in text or a figure legend by a short description of each
3. Comment: a discussion of the clinical relevance of the figure (under the heading "Comment". (Together, the case notes and comment should not exceed 350 words.)
4. Figure and (if applicable) video legends.
5. 7 or fewer references.

The full text of the article appears both in print and online. The print version generally includes 1 image. Up to 5 images may be submitted for the online version. If the paper is accepted, the editors will work with the author to choose which image to display in the print. In addition to images, we encourage (for use online) the inclusion of multimedia components such as PowerPoint, additional images, or video clips.

### *Surgeon's Corner*

This content provides high-quality instruction or an application of a procedure or part of a procedure, designed to aid the practicing obstetrician or gynecologist in improving care. Surgeon's Corner is published in full online; the abstract, manuscript, and a photo or graphic are published in the print journal.

The manuscript must include all of the following:

1. Condensation: a 1-sentence condensation of the paper, consisting of no more than 25 words, to be placed in the Table of Contents.
2. An unstructured abstract of no more than 300 words that summarizes the clinical situation and surgical solution, explains the figure used in the print edition (see item 4), and refers to the video.
3. A description of the clinical situation or problem (under the heading: "Problem") followed by your surgical solution (under the heading: "Our solution"), in 600 words or less (not counting the title page, acknowledgement, references, tables, legends, and figures). Lists and bullet points may be used as appropriate. The text should refer to the figures/photos and video (see items 4 and 5).
4. At least one high-quality photograph (300+ dpi; not taken from a website or cell phone), graphic, or figure, to be published in the print edition; this, plus up to 5 additional photos/figures may be included for the online version.

5. A video clip or computer graphic not longer than 5 minutes, or a **maximum of 50MBs** or less per clip, to be published in the online version.
6. Figure and video legends.
7. 7 or fewer references.

### *Sketches*

These articles describe interesting aspects of medical careers, work life, professional or personal development, or moments of insight, transformation, or inspiration related to professional experiences. Sketches are limited to 1000 words of main text, 7 or fewer references, and require a condensation.

The full-length article appears both in print and on the Journal website.

### **Mixed Media**

Mixed Media may include photos, graphic art, poems, animation, video, interviews, or other forms of creative expression that portray historical or contemporary topics of interest to obstetricians and gynecologists. Typically, Mixed Media articles are published online only; however, applicable portions may appear in the print edition of the Journal. Provide a title suitable for the table of contents.

Authors are encouraged to supply with their manuscripts, for publication, a professional “head shot” of the lead author. This must be a high-resolution digital photograph of at least 300 dpi and not taken from a website or cell phone. Photographs are optional.

### *Letters to the Editors, Replies and Replies*

Every Letter to the Editors, Reply, and Research Letter must include a title page, conflict of interest disclosure, and a Statement of Authorship signed by all authors. These submissions are subject to minor editorial alterations, may be shortened without the authors' approval, and published both in print and on the Journal website.

Per ACOG/SMFM standard practice, letters related to these joint society guidelines are not published. As ACOG and SMFM are interested in feedback, AJOG will forward letters related to guideline articles to the committee and they will reply personally. Please see Clinical Opinion as a venue for presenting a scholarly, evidence-based point of view about controversial issues in OB/GYN.

### **Letters to the Editor and Replies**

Selected Letters to the Editors that cite at least 1 article published in the *American Journal of Obstetrics & Gynecology* within the previous 4 issues are considered for publication.

Letters to the Editors are limited to 3 authors, 400 words (not counting the title page

or references), and 1 to 4 references. At least one of the references must cite the related Journal article(s). All data presented must be fully citable and cited in the supporting reference list.

The editors routinely invite the author(s) of the related article to respond in writing. Published letters are accompanied by either a reply from the original authors or the statement "Reply declined."

### **Research Letters**

Research Letters, not linked to items published in AJOG, briefly summarize the results of original data. Each Research Letter is considered a scientific publication; authors must meet all requirements regarding responsible conduct of research (eg, appropriate IRB approval, data integrity, data retention). Most undergo external peer review. Reviews, case reports, and opinion pieces are not considered for publication under this category.

Research Letters are limited to 7 authors, 500 words (not counting the title page, references, or legend), 5 references and may include either 1 table or 1 figure. Online supplementary materials are not permitted. Research Letters should be formatted similar to the structured abstract guidelines for original research and divided into 4 sections: Objective, Study Design, Results, and Conclusion. Research Letters do not include an abstract or condensation.

### **Editorial Policies**

Queries about submission requirements may be addressed to either of the managing editors:

Sandra Perrine  
perrine@ajog.phxcoxmail.com  
Phone 480-812-9261  
Fax 480-812-9409

Donna L. Stroud  
ajog@rroho.com  
Phone 614-527-3820  
Fax 614-527-3821

### **Ethics of the editorial process**

A policy of the Journal entitled "Specific Inappropriate Acts in the Publication Process" describes the Journal's policies regarding ethical practices, which apply to all submitted articles, whether accepted for publication or not. **Authors must review this document prior to submission.**

Noncompliance with any of the provisions of this policy may lead to an investigation and an editorial judgment. Besides describing issues such as plagiarism and falsification of data, the document named above contains information regarding duplicate publication of which all prospective authors must be aware.

If a report by any or all of the same author(s) has previously been published or is

currently under preparation that deals with the same subjects, animals, or laboratory experiments, and deals with a similar subject as the submitted manuscript, the author(s) are to inform the editors in a cover letter about the similarities and differences of the reports. The editors may request that you upload such reports before further review. This requirement also applies to manuscripts in which subjects, animals, laboratory experiments, or data have been added to those reported previously. Please ensure that the final manuscript includes references for pertinent articles published prior to the publication of the AJOG paper.

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

All submissions are subject to review with iThenticate Professional Plagiarism Prevention. <http://www.ithenticate.com>.

### **Human and nonhuman experimentation**

Authors must follow the ethical standards for human experimentation established in the Declaration of Helsinki (World Medical Association Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925-6). The editors assume that a manuscript emanating from an institution is submitted with the approval of the requisite authority. The authors of reports of human experimentation that require local institutional approval must have obtained this approval **before the experiment was started**; upon request of the Journal editors, the author(s) must provide copies of the appropriate documentation. Institutional approval must be indicated in the Materials and Methods section of the submitted manuscript. If the study is exempt from Institutional Review Board approval, an explanation must be provided under Materials and Methods.

For reports of experiments on nonhuman animals or other species, authors must state under materials and methods that the guidelines for the care and use of the animals approved by the local institution were followed. The type(s) of nonhuman animals or other species used in an investigation must be named in the title, abstract, key words, and materials and methods sections of the manuscript.

For Images in Ob/Gyn, Surgeon's Corner, Viewpoint, or similar reports in which the identity of the patient is potentially identifiable, authors must have obtained written permission from the patient(s) on whom the report is based. The author is responsible for filing this in a secure location. The scope of the consent should allow the author to explicitly disclose the information to Elsevier and for Elsevier to republish the information in print and electronic format including journal web and social media sites. Authors must attest to having obtained written consent in the

manuscript and must be prepared to provide this documentation upon the editors' request.

All research studies, including those involving patients, patient records, research participants or databases, require ethics committee approval (or documented exemption from the Human Subjects Committee) and informed consent (or documented waiver of consent), both of which must be documented in the paper. Studies on patients, patient records, or volunteers require ethics committee approval and informed consent, both of which must be documented in the paper.

### **Trial and research guidelines**

Authors must adhere to the following guidelines when formulating the study.

- **Randomized controlled trial.**

- All Randomized Clinical Trials **require registration** with [clinicaltrials.gov](http://clinicaltrials.gov) (or other registered authority), prior to enrollment. Both the registration site and registration number must **appear on the manuscript title page**.

- Authors are to consult the updated CONSolidated Standards Of Reporting Trials (**CONSORT Statement**): Schulz KF, Altman DG, Moher D, CONSORT Group (2010). CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 7(3): e1000251. doi:10.1371/journal.pmed.1000251. <http://www.consort-statement.org> A flowchart as a figure must be submitted with the manuscript.

- **Systematic review or metaanalysis.** Authors are to consult the **PRISMA Statement**: Moher D, Liberati A, Tetzlaff J, Altman DG, and the PRISMA Group. Preferred Reporting Items for Systematic reviews and Meta-Analyses: the PRISMA Statement. Ann Intern Med 2009;151:264-9. <http://www.prisma-statement.org>

- **Metaanalysis or systematic review of observational studies.** Authors are to consult the **MOOSE Statement**: Stroup DF, Berlin JA, Morton SC, et al, for the Meta-analysis Of Observational Studies in Epidemiology [MOOSE] group. Metaanalysis Of Observational Studies in Epidemiology: a proposal for reporting. JAMA 2000;283:2008-12. <http://www.consort-statement.org/resources/downloads/other-instruments>

- **Diagnostic test(s).** Authors are to consult STAndards for the Reporting of Diagnostic accuracy studies (**STARD Statement**): Bossuyt PM, Reitsma JB, Bruns DE, et al, for the STARD Group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD Initiative. Clin Chem 2003;49:1-6. <http://www.stard-statement.org>

- **Observational study in epidemiology.** Authors are to consult the **STROBE Statement**: von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The STrengthening the Reporting of OBServational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9. [http://www.strobe-](http://www.strobe-statement.org)

[statement.org](http://statement.org) or PLoS Med. 2007 Oct 16;4(10):e296. PMID: 17941714

• **Health economics.** In addition to the general instructions for authors and other guidelines applicable to the study reported in a submitted manuscript (eg, CONSORT guidelines for a randomized controlled trial; see above), authors of health economics manuscripts should consider certain issues specific to such studies and address them in the manuscript and/or submission letter. The checklist specific to this topic must be completed and included with the general submission checklist. [http://cdn.elsevier.com/promis\\_misc/ajoghealth.pdf](http://cdn.elsevier.com/promis_misc/ajoghealth.pdf)

### *Translational Science*

The only type of non-clinical research considered must be translational in nature and contain biological implications for obstetrics and gynecology. Additionally, the direct clinical relevance of every submission is considered when an editorial decision is made. Basic science without direct clinical relevance will not be considered.

As many definitions of basic and translational science abound, please see the following translational science examples to assist you in differentiating study types. If uncertain, authors may email an abstract to either editorial office with an inquiry as to whether or not the submission is encouraged; however, this does not guarantee acceptance.

### *Translational science examples*

#### 1. Ectopic Pregnancy

- Clinical Study: an observational cohort study which shows that patients with a subnormal increase in hCG maternal serum concentration are at increased risk for ectopic pregnancy. [Encouraged submission]
- Translational Science (bench to bedside): proteomic analysis of maternal plasma shows differentially-expressed proteins in patients with ectopic vs. normal pregnancy. Or, an experiment in which the fallopian tubes are ligated in pregnant animals and hCG determinations are measured in maternal serum. [Encouraged submission]
- Translational Science (bedside to community): analysis of techniques to enhance the adoption of best practices in caring for women with ectopic pregnancy [Encouraged submission]
- Basic Science: a description of the glycosylation of protein structure of hCG (even if it is based on the purification of hCG from patients with ectopic pregnancies). [DISCOURAGED submission]

#### 2. Preterm birth

- Clinical Study: an observational study in which a particular biomarker measured in the mid-trimester increases or decreases the risk for spontaneous preterm labor and delivery. [Encouraged submission]



- Translational Science: the transcriptome, proteome, genome, or metabolome of patients who subsequently have spontaneous preterm labor and delivery. [Encouraged submission]
- Basic Science: protein sequence of a particular biomarker. [DISCOURAGED submission]

## **Conflict of interest statement**

### **Authors of all submissions must include a conflict of interest statement.**

Disclosures must include any financial interest present **within the past three years** with commercial entities that are marketing or developing products (drugs, devices, diagnostic tools, etc.) **related to the subject matter of the manuscript**. Disclosures include, but are not limited to: stocks or shares, equity, employment, advisory or scientific board, grant funding, speaker's bureau, paid travel, consulting status, and honoraria. The monetary value of any such stock holdings should be named. No policy could cover every contingency that might be construed as a conflict of interest. Therefore, it is expected that should any potential conflict of interest exist, the authors have revealed this to the editors. All relevant conflicts of interest and sources of funding should be included on the title page of the manuscript at the time of submission under the headings "Conflicts of Interest" and "Source of Funding" which will be published with the article. If the authors report no conflict, a statement of this will be published with the article. Failure to report disclosures may result in sanctions. Use as much or as little detail as appropriate.

#### *Examples:*

- The authors report no conflict of interest.
- R.J.X, M.F., and L.Y.V.R. are employed by the Curette Company, Worthingham, MI. The remaining authors report no conflict of interest.
- R.H. received research funding from PharmaCo, San Antonio, TX, for participating in a multicenter drug trial in 2011-12 S.B. reports no conflict of interest.
- This research was funded, in part, by a grant from the OxyContin Association (A.R.Z.)
- A.E.B. was on the Speaker's Bureau for PharmaCo in 2012.

*Manuscripts written or developed by anyone other than the listed authors should name those individuals in the Acknowledgment(s) section and state their relationship to any commercial enterprise.*

## **Named authors and contributors**

**Every author must provide a signed Statement of Authorship form upon**

**submission.** This requirement applies to all article types including, but not limited to: editorials, mixed media, sketches, letters, and replies.

Authorship requirements for submissions to the Journal must conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals from the International Committee of Medical Journal Editors. <http://www.icmje.org> and [http://www.icmje.org/urm\\_full.pdf](http://www.icmje.org/urm_full.pdf).

Each author named in the byline must qualify by having participated actively and sufficiently in the study reported. The basis for inclusion consists of 2 factors: 1) substantial contributions to (a) the concept and design or analysis and interpretation of data and (b) the author's having drafted the manuscript or revised it critically for important intellectual content; and 2) approval by each author of the version of the manuscript submitted. All conditions (1a, 1b, and 2) must be met. Others contributing substantively to the work, including participants in collaborative trials and persons involved solely in data collection, should be recognized separately in the Acknowledgment(s) section. The corresponding author must confirm that all bylined authors fulfilled all conditions described here.

#### *Authorship by individuals employed by industry*

AJOG values high-quality primary original research reports of industry-sponsored trials and requires appropriate attribution of authors, which may include individuals directly employed by industry (that is, companies producing drugs, devices, tests, equipment or companies with an interest in the topic of the article). However, as of October 1, 2015, AJOG will no longer consider authorship by individuals directly employed by industry for the following categories of manuscripts: Expert review, Systematic review, Clinical opinion, Viewpoint and Call to Action. An individual is considered employed by industry if at least 25% of anticipated annual income is derived from a single manufacturer (as defined above). Individuals not employed by industry may submit manuscripts in these areas with the understanding that the AJOG financial disclosure policy is strictly adhered to.

#### *Changes to authorship*

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

*Before the accepted manuscript is published in an online issue:* Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged, (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement, and (c) written confirmation from that author that he/she meets the criteria for authorship. In the case of addition or removal of authors, this includes confirmation from the author being added or

removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

*After the accepted manuscript is published in an online issue:* Any requests to add, delete, or rearrange author names will follow the same policies as noted above and require an erratum.

#### *Article transfer service*

This journal is part of our Article Transfer Service. This means that if the Editor feels your submission is more suitable in one of our other participating journals, then you may be asked to consider transferring the manuscript. If you agree, the manuscript will be transferred automatically on your behalf with no need to reformat. More information about this can be found here: <http://www.elsevier.com/authors/article-transfer-service>.

#### *Appeals policy*

An author may appeal an editorial decision within 30 days of receipt of the decision to decline a manuscript for publication. The editor's decision may be appealed only if the decision to decline involved a serious mistake, and not merely a judgment call that could have gone either way. Only one appeal is permitted per manuscript, and decisions on appeals are final. New submissions take precedence for the editors over appeals. The basis for an appeal must be set forth clearly and fully in writing to the Editor by the corresponding author.

Please contact one of the managing editors who will forward the written appeal to the Editor. In your appeal letter, state why you think the decision is mistaken and provide your specific responses to any of the reviewers' comments that seem to have contributed to the decision of 'decline to publish'.

### **Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see <https://www.elsevier.com/copyright>). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult

<https://www.elsevier.com/permissions>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <https://www.elsevier.com/permissions>.

For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see <https://www.elsevier.com/OAauthoragreement>). Permitted third party reuse of open access articles is determined by the author's choice of user license (see <https://www.elsevier.com/openaccesslicenses>).

### ***Author rights***

As an author you (or your employer or institution) have certain rights to reuse your work. For more information see <https://www.elsevier.com/copyright>.

### **Funding body agreements and policies**

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some authors may also be reimbursed for associated publication fees. To learn more about existing agreements please visit <https://www.elsevier.com/fundingbodies>. After acceptance, open access papers will be published under a noncommercial license. For authors requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.

### **Open access**

This journal offers authors a choice in publishing their research:

#### ***Open access***

- Articles are freely available to both subscribers and the wider public with permitted reuse.
- An open access publication fee is payable by authors or on their behalf (e.g. by their research funder or institution).

#### ***Subscription***

- Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs (<https://www.elsevier.com/access>).
- No open access publication fee payable by authors.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:

### *Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)*

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The open access publication fee for this journal is **USD 3550**, excluding taxes. Learn more about Elsevier's pricing policy:

<https://www.elsevier.com/openaccesspricing>.

### **Green open access**

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our green open access page for further information (<http://elsevier.com/greenopenaccess>). Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form.

This journal has an embargo period of 12 months.

### **Submission**

Authors must submit all elements of their manuscripts online at <http://ees.elsevier.com/ajog>. Hard-copy submissions will NOT be considered or returned. The online system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision takes place via email.

All policies of the American Journal of Obstetrics & Gynecology, including those related to Conflicts of Interest, Inappropriate Acts, and IRB approval; apply to all submitted articles, including those whose results were presented at professional society meetings.

Submitted manuscripts are screened by Journal staff and editors. For some papers,

a decision is made to decline immediately. All others undergo peer review.

### **Manuscript Submission Checklist**

You are not required to submit the Manuscript Submission Checklist but **must** follow its instructions. The checklist distills many key parts of the Guide for Authors. Incomplete submissions will not be considered.

### **Statement of Authorship**

**Every author on ALL submissions** must sign a Statement of Authorship.

### **Suggested reviewers**

**Required for all submission types** except editorials, letters to the editors, and replies.

Upon submission, authors are required to provide the names, institution, **and email addresses** of 2-3 potential reviewers for editorial consideration. Suggested reviewers may include anyone knowledgeable in the area of study presented. Reviewers should not be mentors or former colleagues, and ideally should not be in the same city as the author (unless there is no person with the needed expertise outside of this city).

### *Previous submission (unpublished)*

Provide a copy of previous peer review comments and a detailed response to each point. This is required for any submission previously submitted to AJOG, optional if previously submitted elsewhere.

### *Submit your article*

Please submit your article via <http://ees.elsevier.com/ajog>.

### *Requirements for the preparation of manuscripts*

**The author(s) accept(s) responsibility that the electronic file is complete and accurate upon submission, revision, and acceptance.**

### **Editing services**

AJOG publishes manuscripts only in American English. This includes using US spelling, punctuation, quotation marks, and decimal points. AJOG editors strongly encourage contributors whose English is not excellent to have their manuscripts edited by a professional translator or native English speaker before submission. Elsevier offers authors two services to help prepare their manuscripts for submission to an English-language journal.

The first service edits your manuscript already written in English to ensure it is in correct scientific English. This process does not change the content of your manuscript but improves understanding and readability for an English-speaking reader. This process takes less than six business days and the cost of an average manuscript is less than \$400. Please visit <http://webshop.elsevier.com/languageediting/pages/howdoesitwork.html> for more details and to upload your manuscript.

The second service translates your manuscript from your language (Chinese, Portuguese or Spanish) into either British or American English. This process is carried out by Language experts within your field, and takes less than 11 business days. The average cost is \$1,000. Please visit <http://webshop.elsevier.com/languageservices/translationservices/pages/howdoesitwork.html> for more details and to upload your manuscript.

Please note that these services are not mandatory for publication in an Elsevier journal. Using these services does not guarantee selection for peer review or acceptance, and you are not obligated to submit your edited manuscript to an Elsevier journal. Visit our [customer support site](#).

### **Use of word processing software**

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier: http://www.elsevier.com/guidepublication](http://www.elsevier.com/guidepublication)). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

## Basic Format

Requirements for manuscripts submitted to the Journal generally conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals from the International Committee of Medical Journal Editors ( <http://www.icmje.org>).

Manuscripts must be submitted in American English, double spaced, with a font size no smaller than 12. Number pages consecutively in the upper right corner in the following order: title page, condensation and short version of title, abstract, main text, acknowledgments, references, tables, and figure legends.

IMPORTANT: Figures are to be uploaded individually and in separate files (one figure per file). **DO NOT embed the figure into the manuscript text file**, as this compromises the image quality, creating an unpublishable image (see artwork).

## Use of Statistics and Math Formulae

In describing the statistical analyses performed, state which tests were used to evaluate a specific data set. In tables, indicate which statistical test(s) were used to evaluate the data.

Present simple formulae in the line of normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, eg, X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

## Abbreviations, units, proprietary (brand) names, and symbols

Use only standard abbreviations. Do not use abbreviations in the title or in the abstract. In the text they should be kept to a practical minimum. The full word or phrase for which an abbreviation stands should precede its first use in the text, with the abbreviation following in parentheses, unless it is a conventional standard unit of measurement.

The use of conventional units of measure is recommended, followed by Système International d'Unités (SI) units in parentheses. For this and other issues of style, authors are advised to consult the current AMA style manual: Iverson C, Christiansen S, Flanagan A, et al. *AMA manual of style: a guide for authors and editors*. 10th ed. New York, NY: Oxford University Press; 2007.

Generic, chemical, and/or proprietary names of drugs may be used. When a generic



or chemical name is used, authors may insert the proprietary name in parentheses after the drug's first mention in the text (optional). When a proprietary drug name is used, it should be followed parenthetically (at first mention only) by the full name of the manufacturer and the city and state (US) or the city, province (if appropriate), and non-US country in which its main headquarters are located. Proprietary (brand names) are not permitted in the manuscript title.

Do not insert in any part of the paper the symbol for copyright (©), registered trademark (®), or trademark (TM); if included, they will be removed before publication.

### *Permissions*

Direct quotations, tables, figures, and any other material that has previously appeared in copyrighted material must be accompanied by written permission for their use from the copyright owner and original author(s) along with complete reference information. Photographs of identifiable persons either must be accompanied by signed releases or all recognizable features must be masked.

### **Article structure**

#### **Essential title page information**

**Title page (starting on page 1)** – required for ALL article types, including: letters, replies, and online-only content – includes the following sequence:

**1)** Title (as concise as possible, approximately 12 words, without abbreviations or parenthetical abbreviations for terms used in the title, and suitable for indexing purposes) Proprietary (brand names) and conclusion statements are NOT permitted in the manuscript title

**2)** List of authors to be credited (byline), including each author's first name, middle initial, and LAST NAME (surname in all capital letters), with highest academic degrees (honorary degrees are not permitted); city or cities, state(s), province (Canada and Australia), and country or countries other than the United States in which the study was conducted; divisional and/or departmental and institutional affiliations of each author at the time the study was performed; **for authors not called "Doctor," indicate Ms. or Mr.**

**Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

**3)** Disclosure statement of any potential of interest for each author; if no conflict

exists; include the statement “The author(s) report(s) no conflict of interest.”

**4) Any source(s) of financial support for the research**

**Role of the funding source.** You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

**5) Required for clinical trials – include the clinical trial identification number and the URL of the registration site**

**6) Paper presentation information:** if the findings were presented at a meeting, include the name of the meeting and its number (eg, “the 24th Annual Scientific Meeting” or “the 12th annual meeting”), the organization presenting the meeting, the city and state or city and non-US country (for Canada and Australia, include the province) in which the meeting was held, and the month, **inclusive dates**(not only the date on which the specific presentation was made), and year of the meeting

**7) Disclaimer, if appropriate, such as for authors employed by the Federal Government or Armed Forces**

**8) The corresponding author's contact information (who will handle correspondence at all stages of submission, publication, and post-publication). Contact details must be kept up to date by the corresponding author. Include the full name, address, work and home and/or cell phone numbers (indicating which is which), fax number, and email address.**

*Word count*

The word count of both the abstract and the main text (not counting the title page, condensation, acknowledgements, references, tables, figure legends, and figures) must be included at the bottom of the title page. For Original Research and Reports of Major Impact: under the word counts, identify which 1 figure OR 1 table is to appear in the print issue should the submission be accepted for publication.

*Condensation and short version of title*

On the next page of the manuscript, supply:

- a 1-sentence condensation of the paper, consisting of no more than 25 words, stating its essential point(s); this sentence, which is subject to copy editing in conformance with Journal style, will appear in the Table of Contents, and
- a short version of the article title, for the identification line inserted at the bottom of each published table and figure.

### **Abstract page, including key words/phrases**

On the next page of the manuscript, provide an abstract and as many **alphabetized** key words or short phrases as needed for indexing.

Abbreviations and references are NOT permitted in the abstract (structured nor unstructured). Required abstract formats are described under the Article Types section of this document.

### *Text*

The editors require that original research articles be organized into sections and identified with the following headings: (not applicable to review articles, clinical opinion, or other article types.)

The type(s) of non-human animals or other species used in an investigation must be named in the Title, Abstract, and Materials and Methods sections of the manuscript.

### **Introduction**

State concisely the study's purpose and rationale. Present only the background, supported by a limited number of pertinent references necessary for the reader to understand why the study was conducted. Do not include study data or conclusions.

### **Materials and Methods**

Describe briefly, but in sufficient detail to permit others to replicate the study, its plan, patients, experimental animals or other species, materials, and controls; methods and procedures; and statistical method(s) employed. Institutional Review Board (IRB) issues are to be addressed here as stated under "Human and nonhuman experimentation" in the Editorial Policies section above. If the study was exempt from IRB approval, provide an explanation in the Materials and Methods section of the paper.

### **Results**

This section includes detailed findings and must cite, in numerical order, all tables and/or figures, which should supplement, not reiterate, the text. Emphasize only the most important observations. Reserve any comparisons with others' observations for the Comment section (see below).

**Comment**

Do not repeat the details of data presented under Results or present any new data here. The editors strongly advise the following structure:

- A brief statement of the principal findings, limiting claims to those strictly supported by the data, avoiding speculation and overgeneralization. Give equal emphasis to positive and negative findings of equal scientific merit.
- Strengths and weaknesses of the study, both intrinsically and in relation to other studies, particularly any differences in results.
- The meaning of the study; eg, hypothesized mechanisms that might explain the outcomes observed and/or the implications for clinicians or policy makers. Indicate whether additional research is required before the information can be confidently used in clinical settings.
- Unanswered questions; proposals for future research.

**Acknowledgment(s)**

This section thanks those other than the authors who have made substantive contributions to the manuscript, including participants in collaborative trials and persons providing only data collection or assistance with preparing the paper for submission or publication. Name only those who have made substantive contributions to the study (see “Editorial Policies”).

For each person named under Acknowledgments, including science writers, the following information must be provided: name, place of employment, funding source(s), and disclosure of source of compensation, whether financial or in the form of services or complimentary products. All individuals named in this section must consent to such acknowledgment.

**References**

Follow the format in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals from the International Committee of Medical Journal Editors. <http://www.icmje.org> Standard journal title abbreviations are available in the List of Serials Indexed for Online Users from the National Library of Medicine. [http://www.nlm.nih.gov/tsd/serials/terms\\_cond.html](http://www.nlm.nih.gov/tsd/serials/terms_cond.html)

**Numbering and order**

All references are to be numbered sequentially as they fall in the text. For references

that are not cited in the main text but only within table(s) or figure(s), begin such numbering *after* the numbers in the main reference list.

Insert citations in Arabic numerals as superscripts, not in parentheses. If the reference follows a comma or falls at the end of a sentence, the superscript should follow the comma or the period.

Do not include the first author of the cited reference in the text, in parentheses or otherwise, except as part of the text itself (Smith et al found.... or In a study by Smith et al, ....).

If any reference is repeated or out of order, the author is responsible for renumbering references as needed prior to submission or resubmission. If any reference(s) are added or deleted during editing, the author is responsible for renumbering all subsequent references, both in citations within the text (and tables and figures) and, correspondingly, in the reference list. For any citations used in tables or figure legends, renumbering should similarly be done there.

### **Reference style**

In general references follow AMA style.

For up to 6 authors, list all; for 7 or more authors, list the first 3 + et al.

#### **•Journal article**

Nageotte MP, Vander Wal B. Achievement of the 30-minute standard in obstetrics—can it be done? *Am J Obstet Gynecol* 2012;206:104-7.

#### **•Book chapter or section**

Kim M. Amenorrhea: primary and secondary. In: Zuspan FP, Quilligan ED, eds. *Handbook of obstetrics, gynecology, and primary care*. St Louis, MO: Mosby; 1998:3-10.

#### **•Personal communications; unpublished data**

If essential, these may be cited, within parentheses, at an appropriate location in the text, but not as numbered references. Written, signed permission from individual(s) quoted *must accompany the manuscript upon submission*.

for additional examples see any recent issue of the Journal.

### **Abstracts**

Published abstracts may not be cited; citing the complete published article is preferred.

### **Journal abbreviations source**

Journal names should be abbreviated according to the List of Title Word Abbreviations: <http://www.issn.org/services/online-services/access-to-the-ltwa/>.

### **Provisional patent applications**

Provisional patent applications may not be cited as a reference.

### **Reference links**

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

### **References in a special issue**

Please ensure that the words 'this issue' are added to any references in the list (and add any citations in the text) to other articles in the same Special Issue.

### **Web references**

Websites may or may not be appropriate sources for citation; e.g., websites that serve as repositories of genetic information maintained by NIH, NCI, and the National Library of Medicine are acceptable.

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

### **Tables**

Submit tables in the manuscript file at the conclusion of the reference list and before the figure legends. Create all tables as double-spaced text in Microsoft Word. Any table submitted as a \*.jpg or \*.tif file will be returned for replacement.

Identify each table with a *brief* title (as few words as possible; reserve abbreviations for the key) and with an Arabic number (Table 1, Table 2, etc.) in the order in which it is cited in the text. Each column, including the first, must have a heading. Put all

explanatory matter in footnotes, including the spelling out of any nonstandard abbreviations used in the table.

For footnote symbols within tables, follow the style and order noted on pages 90-95 of the AMA style guide, 10th edition. For placement, start in the upper left corner and work across, left to right, and down, line by line.

If a table, in whole or in part, was derived from copyrighted material, a footnote at the bottom of the table must credit the original source, cited fully. Any copyrighted material must be accompanied by a **letter or completed permission form** at the time of manuscript submission.

### *Figure captions*

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

### *Supplementary data*

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <http://www.elsevier.com/artworkinstructions>.

### *Appendices*

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

### *Figure legends*

On the final page of the manuscript supply the following for each figure: The figure number, figure title, and a 1- or 2-sentence description (legend, caption). Explain any arrowhead, letter, or other symbol used to identify parts of a photograph, drawing, or other illustration. Spell out any abbreviations used. In photomicrographs, explain the internal scale and identify the method of staining, if appropriate. If a figure was previously published by any of the bylined authors or others, insert a statement

that permission has been granted and by whom, as well as a full citation of the original publication.

## Figures

There is no change for the use of color figures.

1. Submit each figure individually (one figure per file).
2. DO NOT copy and paste or embed images into the manuscript text file or in a slide presentation. This compromises image quality making it unpublishable.
3. Preferred image formats are: EPS, TIFF, or JPEG.
4. Number figures sequentially in order as they appear in the text, with Arabic numbers (Figure 1, Figure 2, Figure 3A, etc).
5. Assign to each figure a brief title (containing as few words as possible and reserving abbreviations for the legend).

For further explanation and examples of artwork preparation, see artwork instructions to authors from AJOG's publisher at <http://www.elsevier.com/artwork> (click on "Artwork and Multimedia Instructions Interactive PDF").

## Videos and computer graphics

Authors are encouraged to submit videos and computer-generated graphics; eg, a slide presentation with or without animation and sound. Although the publisher will not edit any video or computer graphic, the editors and reviewers may suggest changes. Any patient identification must be removed or masked. If music is utilized, appropriate permission is required.

Videos must be compatible with Windows Media Player and submitted in MPEG-1 or MPEG-2 (\*.mpg) or QuickTime (\*.mov) format. The maximum length of a video or computer graphic is 50 MBs or less per clip. Longer submissions may be divided into smaller clips, each of which should be identified at the beginning of that section; eg, Video Clip 1, Graphic 1. A concise legend for each video clip or computer graphic presentation must be included with the manuscript.

Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data.

For more detailed instructions please visit our video instruction pages at <http://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.



Videos and computer graphics accompanying a manuscript that is declined for publication will not be accepted separately. If the manuscript is accepted for publication, the presentation will be in the electronic version of your article, and in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>.

### **Illustration services**

Elsevier's WebShop ( <http://webshop.elsevier.com/illustrationservices>) offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

### **Artwork**

#### *Electronic artwork*

You are urged to visit the electronic artwork site (<http://www.elsevier.com/artworkinstructions>); some excerpts from the detailed information are given here:

#### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the printed version.
- Submit each illustration as a separate file.

### *Formats*

EPS (or PDF): Vector drawings, embed all used fonts.  
 TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

### **Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

### *Reference management software*

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles ( <http://citationstyles.org>), such as Mendeley ( <http://www.mendeley.com/features/reference-manager>) and Zotero ( <https://www.zotero.org/>), as well as EndNote ( <http://endnote.com/downloads/styles>). Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/american-journal-of-obstetrics-and-gynecology>

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

### **3D radiological data**

You can enrich your online article by providing 3D radiological data in DICOM format. Radiological data will be visualized for readers using the interactive viewer embedded within your article, and will enable them to: browse through available radiological datasets; explore radiological data as 2D series, 2D orthogonal MPR, 3D volume rendering and 3D MIP; zoom, rotate and pan 3D reconstructions; cut through the volume; change opacity and threshold level; and download the data. Multiple datasets can be submitted. Each dataset will have to be zipped and uploaded to the online submission system via the '3D radiological data' submission category. The recommended size of a single uncompressed dataset is 200 MB or less. Please provide a short informative description for each dataset by filling in the 'Description' field when uploading each ZIP file. Note: all datasets will be available for download from the online article on ScienceDirect. So please ensure that all DICOM files are **anonymized** prior to submission. For more information see: <https://www.elsevier.com/about/content-innovation/radiological-data>

### **Virtual Microscope**

The journal encourages authors to supplement in-article microscopic images with corresponding high resolution versions for use with the Virtual Microscope viewer. The Virtual Microscope is a web based viewer that enables users to view microscopic images at the highest level of detail and provides features such as zoom and pan. This feature for the first time gives authors the opportunity to share true high resolution microscopic images with their readers. More information and examples are available at <https://www.elsevier.com/about/content-innovation/virtual-microscope>. Authors of this journal will receive an invitation e-mail to create microscope images for use with the Virtual Microscope when their manuscript is first reviewed. If you opt to use the feature, please contact [virtualmicroscope@elsevier.com](mailto:virtualmicroscope@elsevier.com) for instructions on how to prepare and upload the required high resolution images

